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ABSTRACT 
Hyperpigmentation is a common dermatological complaint that can have 
profound effect on appearance and quality of life.  Disorders of hyperpigmentation 
comprise a large group of skin conditions characterized by an increase of melanin 
production, increase in density of active melanocytes, abnormal melanin distribution, 
and/or deposition of exogenous pigments.  
This cross-sectional study was conducted to evaluate the impact 
hyperpigmentation disorders on health-related quality of life and to better understand 
patient knowledge, approaches, and experiences. The study was conducted on 298 
consenting adult patients with a skin related disorder of hyperpigmentation who sought 
dermatological care at Boston Medical Center (BMC) or East Boston Neighborhood 
Health Center (EBNHC) from February of 2015 to March of 2016. Patients were 
anonymously surveyed in order to collect an assortment of information including 
demographic characteristics, skin condition, health practices, knowledge base, and 
health-related quality of life (HRQoL) measured with the Dermatology Life Quality 
Index (DLQI) (Finlay and Khan 1994) and SDIEQ, a five-item , non-validated, brief 
health-related quality of life questionnaire (A. Taylor et al. 2008). Disease severity was 
		 vii 
assessed by Melasma Area Severity Index (MASI), Post Acne Hyperpigmentation Index 
(PAHPI), and body surface area when appropriate. 
The mean overall DLQI was 6.56 (SD ±5.35). In sub-analysis, the mean DLQI in 
those diagnosed with post-inflammatory hyperpigmentation was 7.89 (SD ± 0.61), 
melasma 6.75 (SD ± 0.45), and other hyperpigmentation disorders 4.5 (SD ± 0.55). The 
disease type and duration were both factors associated with a change in DLQI scores. 
The factors associated with a higher likelihood of patients’ knowledge of their diagnosis 
included a higher level of formal education, younger age, longer duration of having the 
condition, and current use of sunscreen, which were found to have 2.4, 2, 3.7, and 2.4 
significantly higher odds of knowing their diagnosis, respectively. 
This study found that the overall impact of hyperpigmentation on health-related 
quality of life (HRQoL) was small to moderate; however, about 22% reported a very 
large effect on quality of life. Patients with post-inflammatory hyperpigmentation (PIH) 
and melasma have significantly lower quality of life when compared with other 
hyperpigmentation disorders. MASI had a significantly weak correlation with DLQI and 
SDIEQ, demonstrating that disease severity does not predict patient perception and 
impact on quality of life. 
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CHAPTER ONE: INTRODUCTION 
 
Skin hyperpigmentation is a common dermatological complaint that may affect 
patients’ appearance and quality of life.  It comprises a large group of skin conditions 
characterized by an increase in melanin production, an increase in density of active 
melanocytes, abnormal melanin distribution, and/or deposition of exogenous pigments. 
This common dermatological condition may occur in any Fitzpatrick skin type; however, 
darker skin phenotypes are typically more frequently affected due to differences in 
structure and function, including melanin content and melanosomal dispersion 
patterns.  There are several skin disorders that may present clinically as 
hyperpigmentation, including melasma, lentigines, post-inflammatory 
hyperpigmentation, and several others.   
 
Those with darker skin phenotypes, or skin of color, constitute a wide range of 
racial and ethnic groups traditionally referring to persons of African, Asian, Native 
American, Middle Eastern, and Hispanic backgrounds.  Disorders of hyperpigmentation 
are expected to become far more common as by 2050, nearly one-half of the U.S. 
population will be considered nonwhite or skin of color.  To date, the true prevalence of 
hyperpigmentation in the US is unknown due to data being grouped under the ICD-9 
code of dyschromia, which includes disorders of both hyperpigmentation and 
hypopigmentation (S. J. Kang et al. 2014). The literature show that the prevalence (rate) 
of hyperpigmentation disorders in Hispanic and Latino population is around 6  to 7.5% 
(M. R. Sanchez 2003). Although this rate is lower than the prevalence of 
		
2 
hyperpigmentation among African Americans 19.9% (Alexis, Sergay, and Taylor 2007) 
and Afro-Caribbean  22.8% (Dunwell and Rose 2003) it is higher when compared with 
Caucasian population. In addition, despite numerous studies evaluating quality of life in 
melasma (Pawaskar et al. 2007) (Ikino et al. 2015) (Pichardo et al. 2009), little is known 
about health-related quality of life of other common hyperpigmentation disorders (A. 
Taylor et al. 2008).  
 
Although few dermatological disorders affect life expectancy, many occur as 
chronic conditions that impair patients’ life in innumerable other ways.  Most disorders of 
hyperpigmentation do not affect physical health, yet they have an impact on other aspects 
of individuals’ health including emotional, social, and family well-being. Measuring how 
dermatological conditions affect lives and quantifying disease burden may be considered 
a “vital sign”, and this information should be used to improve patients’ lives and can also 
be used for health policy (Chen 2012). Moreover, measurement of clinical disease 
severity, often used by clinicians as for treatment guidelines, may not correlate well with 
patients’ perception and feelings towards their disease condition.  
 
This thesis investigates the impact of skin hyperpigmentation disorders on 
patients’ quality of life along with knowledge, attitudes, and practices towards their skin 
disorder(s).  This thesis also aims to find out which factors are associated with a higher 
impact on quality of life and knowledge of a diagnosis. A thorough understanding of 
patients’ skin practices and perceptions regarding their skin hyperpigmentation is of great 
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importance when caring for those afflicted.  
 
Chapter 2 will include a review of the literature and will discuss the most 
common causes of cutaneous hyperpigmentation disorders. Chapter 3 comprises study 
design and methodology. Chapter 4 describes the study results, Chapter 5 aims to discuss 
our findings, and Chapter 6 concludes the thesis and summarizes this contribution. 
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CHAPTER TWO 
 
 This chapter will review basic aspects of the skin, including structure and 
function, physiology, and signaling pathways involved in hyperpigmentation disorders.  
It will also give an overview of the most common diagnoses found in our study 
population. 
  
2.1 Skin Color 
Skin tone varies among individuals of different races and ethnicities. The 
observed skin color results from a complex combination of biochemical and physical 
factors including the amount, type and distribution of melanin, its location within the 
epidermis or dermis, vascular density, and presence of exogenous chromophores.  
 
Chromophores are classified as melanotic and nonmelanotic. Melanocytic 
chromophores are composed of melanin (eumelanin and pheomelanin), melanocytes, and 
melanin in melanophages. Nonmelanotic (chromatics) components are collagen, carotene 
or lycopene, chemicals, drugs, and oxyhemoglobin among others (Nordlund et al. 2006). 
 
Melanin is by far the most important determinant of skin color. The variations in 
skin color are due to different concentrations of eumelanin (brownish-black) and 
pheomelanin (reddish-yellow). The melanin in the skin is either a constitutive 
pigmentation determined genetically or facultative pigmentation, which is temporary skin 
pigmentation in response to UVR exposure (Jablonski 2004).  
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 Other factors such as hemoglobin and oxyhemoglobin are nonmelanotic 
(chromatics) that by the absorption of a specific wavelength allow for the reflection of 
red giving the pink/red skin coloration that is easily observed in Caucasian skin. 
Lycopene and beta-carotene are implicated in the yellow hues of skin color.  Other skin 
hues are made from dermal collagen which makes the skin appear whitish and also 
exogenous factors like dermal drug deposition which may cause a blue-gray discoloration 
(Rawlings 2006). The components of the pigmentary system and the multiple and 
complex factors that regulates melanin pigmentation is briefly discussed below. 
 
 
2.1.2 Melanocytes 
Melanocytes are pigment-producing cells located in the stratum basale of the 
epidermis among other locations (hair matrix, outer root sheath of hair follicles, uveal 
tract, leptomeninges, inner ears).   They are derived from the neural crest by migration 
via dorsolateral path or derived from Schwan cell precursors by migration via ventral 
path (Adameyko et al. 2009) during the 18th week of fetal development. Melanocytes are 
responsible for melanin synthesis.  Once synthesized, melanin is stored within the 
melanosome and moved along the dendrites to reach the neighboring keratinocytes. 
(Park, Yaar, 2012).   
 
The number of melanocytes may vary from one body part to another; however, 
they do not differ in number from one individual to another. The difference in skin color 
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are due to number, size, and aggregation of the melanosomes contained in the 
melanocytes and keratinocytes rather than the number of melanocytes (S. C. Taylor 
2002).  
 
 
2.1.2 Melanosomes 
Melanosomes are specific melanin-containing organelles that belong to the family 
of lysosomal-related organelles (LROs). They are classified according to the type of 
melanin they produce. Their maturation follows four distinct stages. Stage I melanosomes 
are derived from the endoplasmatic reticulum and contain an amorphous matrix and no 
melanin. Stage II consists of tyrosinase enzyme and other protein assembly, without 
melanin synthesis. Stage III involves deposition of melanin on internal fibrils. The final 
stage IV melanosomes are fully melanized and ready to be transferred to neighboring 
cells via melanocyte dendrites (Yamaguchi and Hearing 2009). 
 
The size, aggregation, and distribution of melanosomes are influenced by 
racial/ethnic background and sun exposure (Szabo, 1969). Dark-skinned individuals and 
areas of sun exposure have predominantly larger, nonaggregated melanosomes that are 
densely distributed along the basal layer. While lighter skin types exhibit smaller, 
aggregated, and less dense melanosomes located more prominently in the stratum 
corneum (Taylor, 2002).  
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2.2  Biology of Melanin and Melanogenesis 
Melanin is a polymer attached to a protein that protects the skin against UV damage. 
There are two types of human melanin: eumelanin and pheomelanin. The synthesis of 
both is derived from the amino acid tyrosine, which is converted to 3,4 –
dihydroxyphenylalamine (DOPA) by tyrosinase enzyme (TYR). This is an essential step 
for melanin formation. DOPA is again converted to DOPAquinone by the same 
tyrosinase enzyme. DOPAquinone can be converted into 5,6-dihydroxyindole (DHI) 
forming a dark brown-black virtually insoluble polymer or 5,6-dihydroxyindole-2-
carboxylic acid (DHICA) forming the light-brown alkali soluble eumelanin. When 
DOPAquinone is associated with glutathione or cysteine, it forms cysteinylDOPA, which 
becomes the yellow/red, soluble, low-molecular-weight, and alkali soluble pheomelanin 
(Rawlings 2006). 
 
The concentration of the two types of melanin varies according to skin type. Dark-
skinned individuals have higher concentration of eumelanin, whereas red-haired 
individuals have a pheomelanin rich phenotype (Jablonski 2004). 
 
 
2.3 Regulation of Melanocytes  
Multiple signaling pathways and transcription factors regulate melanin synthesis, 
transport, and transfer. These include melanocyte stimulating hormone (MSH)/cyclic 
adenosine monophosphate (cAMP), KIT, and Wnt signaling pathways. These signaling 
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pathways control the expression of transcription factors such as melanocortin-1 receptor 
(MCR1), microphthalmia-associated transcription factor (MITF), PAX3, SOX9/10 
among several others that are involved in both congenital and acquired disorders of 
hyperpigmentation (J. Y. Lin and Fisher 2007) (Bertolotto et al. 1998).  
 
The regulation of melanin production can be divided into proteins involved in the 
structure of melanosomes (Pmel17, Mart-1, and GPNMB), proteins that regulate 
synthesis of melanin ( TYR, TRYP1, DCT, BLOC-1, OA1, P, and SLC45A2), and 
proteins involved in intracellular trafficking and transport of melanosomes (microtubules, 
F-actin, kinesin, dynein, RAB27a, melanophilin, myosin and others) (Yamaguchi and 
Hearing 2014). Disorders of hyperpigmentation may be a result of a dysregulation of 
these signaling pathways along with gene mutations and endogenous or exogenous 
pigment deposition.  
 
 
2.4 Disorders of hyperpigmentation  
Hyperpigmentation and/or hyperchromia encompasses a wide range of 
dermatological disorders that are very common worldwide. As the United States 
population becomes more racially and ethnically diverse, this cosmetic and sometimes 
psychologically devastating group of conditions will pose greater challenges for 
physicians.  
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There is limited literature assessing the prevalence of hyperpigmentation in the 
United States population.  In addition, the true prevalence of hyperpigmentation is 
obscured by most of the data being grouped under the International Classification of 
Diseases (ICD-9) code of dyschromia, which includes both hyperpigmentation/ 
hyperchromic and hypopigmentation/hypochromic disorders.   
 
Disorders of hyperpigmentation are characterized by an increase in either melanin 
and/or melanocytes.  Hyperpigmentation can be localized, generalized, or have a variable 
distribution pattern. Furthermore, it can be classified according to histological evaluation 
of pigment location: epidermal, dermal, or mixed. In 2006, Nordland et al. proposed a 
scheme  to proper classify disorders of pigmentation (Table 1, 2 and 3) (Nordlund et al. 
2006).  
 
In order to have a uniform terminology when referring to pigmentary disorders, 
the consensus lexicon was developed by the Pigmentary Disorders Academy (PDA).  The 
classification is based on two distinct chromophores (melanotic or nonmelanotic), 
location within skin layers (epidermal, dermal, or mixed), and genetic or non-genetic 
(Tables 1, 2 and 3). 
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Melanotic (Hyperpigmentation) 
Hypermelanosis Hypermelanocytosis 
Congenital Acquired 
Localized Variable Generalized 
Epi Der Mix Epi Der Mix Epi Der Mix 
Table 1. Classification of disorder of hyperpigmentation. Epi, epidermal, Der, dermal 
and Mix, mixed (Adapted from Nordlund et al., 2006). 
 
Nonmelanotic factors that affect the skin color are known as chromatics. They 
include chemicals, drugs, deposits, carotene or lycopene, and an increase or reduction of 
normal skin components such as collagen and hemoglobin. Skin disorders due to 
nonmelanotic chromophores are called dyschromias, with abnormal darkening due to 
these factors known as hyperchromias (Table 2). 
 
Nonmelanotic (Hyperchromia) 
Congenital Acquired 
Localized Variable Generalized 
Epi Der Mix Epi Der Mix Epi Der Mix 
Table 2. Classification of nonmelanocitic types of hyperchromia. Epi, epidermal, Der, 
dermal and Mix, mixed (Adapted from Nordlund et al., 2006). 
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	 The combination of increased melanotic and nomelanotic factors may occur, the 
co-existence of this pigmentary change is called mixed hyperpigmentation and 
hyperchromia respectively (Table 3).   
 
Mixed Hyperpigmentation and 
Hyperchromia 
Congenital Acquired 
Localized Variable Generalized 
Epi Der Mix Epi Der Mix Epi Der Mix 
Table 3. Classification of mixed hypermelanosis and hyperchromias. Epi, epidermal, 
Der, dermal and Mix, mixed (Adapted from Nordlund et al., 2006). 
 
2.4.1 Melasma 
Melasma is a common acquired hyperpigmentation disorder that involves 
primarily sun-exposed areas on the face and less often on the neck and arms in those with 
Fitzpatrick skin phototypes III to VI (J P Ortonne et al. 2009). It is more common in 
women than men. The use of hormonal contraception, pregnancy, and sun exposure are 
common associated factors (J P Ortonne et al. 2009).  
 
 The overall prevalence of melasma is unknown. Reported prevalence rates vary 
among studied populations, documented rates include 40% of Southeast Asians and 10% 
of Latin American females. The highest prevalence is observed during pregnancy, 
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occurring in 10–70% of women (Doris Hexsel et al. 2013), and lowest prevalence among 
men, occurring in 14.5–20% (Pichardo et al. 2009).  
 
A combination of genetic background, sun exposure, hormones, and Fitzpatrick 
skin phototype are thought to be the main contributing etiopathogenic factors in the 
development of melasma (Passeron 2013). 
 
Several epidemiological studies suggest a positive family history, with rates 
ranging from  10.3% (Goh and Dlova 1999) to 56.3% (Tamega et al. 2013). A study by 
Kang et al., using gene expression profiling, identified 279 genes that were found to have 
different expressions in melasma lesional and perilesional skin. Among those, 4 genes 
(TYR, TYRP1, DCT, and SILV) involved in melanin biosynthesis were up regulated in 
lesional skin. In addition, Wnt inhibitory factor-1, a Wnt antagonist, was decreased in 
lesional skin resulting in upregulation of the Wnt signaling pathway and subsequent 
melanogenesis (Hee Young Kang et al. 2011). 
 
Sun exposure is known to directly induce melanogenesis, melanocyte 
proliferation, migration, and indirectly stimulate cytokines, including interleukin-1, 
endothelin-1, alpha-melanocyte-stimulating hormone, and adrenocorticotropic hormone 
by the UV activated keratinocytes (V. M. Sheth and Pandya 2011a). It appears that 
melanocytes are not the only culprits cells on the pathogenesis of melasma; new evidence 
suggests that a rather complex cellular interaction involving keratinocytes, dermal 
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fibroblasts, mast cells, skin vasculature, and hormones contribute to the effect of UVR on 
melasma (Lee 2014).  
 
Kang et al. reported that UVR induces dermal inflammation by activation of 
fibroblasts, upregulation of stem cell factors and c-kit, resulting in melanocyte 
proliferation and stimulation of melanogenesis (H. Y. Kang et al. 2006). Moreover, 
visible light (VL, 400–780nm) may also play a role in the pathogenesis of melasma, 
especially in Fitzpatrick skin types IV–VI. (Castanedo-Cazares et al. 2014) (Passeron 
2013). 
 
Although the role of hormones in melasma is unclear, epidemiological studies 
suggest an association with oral contraceptive, pregnancy, and onset during reproductive 
years indicating an influence of sex hormones (Lee 2014). Estrogen receptors (ER) are 
commonly expressed in the skin. Immunohistochemical studies revealed increased 
expression of ERs in the dermis of melasma lesional skin (Lieberman R 2008) and 
progesterone receptors in the epidermis of lesional skin in contrast with normal skin 
(Jang et al. 2010). When estrogen binds to estrogen receptors (ERs) present in 
melanocytes and keratinocytes, cAMP- protein kinase A (PKA) is activated and 
upregulation of pathways [(cAMP responsive-element binding protein (CREB), 
Microftalmia associated transcription factor (MTIF), tyrosinase (TYR)] involved in 
melanin synthesis are activated. Moreover, upregulation of PDZ domain kidney 1 
(PDZK-1) protein, a member of the sodium-hydrogen exchanger regulatory factor family, 
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further facilitates estrogen action and increases melanogenesis and melanosome transfer 
in melasma lesional skin (Lee 2015). 
 
Clinically, melasma is characterized by light to dark brown facial patches, 
distributed in three distinct clinical patterns: centrofacial, malar, and mandibular (N. P. 
Sanchez et al. 1981). Another classification, based on pigment location within skin layers 
assessed with a wood’s lamp (320–400nm) examination, may be used to predict 
treatment outcome. Melasma can be classified into four types. Epidermal, when color is 
enhanced under wood’s lamp examination, dermal when lesions becomes less apparent, 
mixed if both features are present, and inapparent or indeterminate, when no difference in 
color is appreciated.  Innapparent or indeterminate is more commonly seen in darker skin 
types (Gilchrest et al. 1977). 
 
Recent studies, however, suggest that the pigment deposition does not always 
correlate well with the wood’s lamp evaluation. A study conducted by Grimes et el. 
examining biopsies of lesional skin revealed presence of pigment in both the epidermis 
and dermis of patients previously characterized as having an epidermal only pattern by 
wood’s light examination (Grimes, Yamada, and Bhawan 2005).   
 
On histopathology, melasma lesional skin reveals increased deposition of 
epidermal melanin without a quantitative increase in the number of melanocytes (Grimes, 
Yamada, and Bhawan 2005), solar elastosis, and mast cells. Melanophages may be seen 
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in the papillary dermis (W. H. Kang et al. 2002).  There are some studies that report an 
increased number of melanocytes (N. P. Sanchez et al. 1981), increased number of 
inflammatory cells (Noh et al. 2014), and vascularity in melasma lesional skin (Kim et al. 
2007). 
 
Despite being an asymptomatic disorder, melasma causes emotional and 
psychosocial distress in those afflicted. The impact of melasma on patient quality of life 
(QoL) has been assessed in a few studies using the Melasma Quality of Life scale 
(MELASQoL), a validated disease specific 10-item instrument. The majority of studies 
have found that the most adversely affected domains were quality of life, 
recreation/leisure, and emotional well-being (Balkrishnan et al. 2003).  
 
A study conducted on 51 Brazilian females to assess the quality of life (Qol) using 
the Melasma Quality of Life Scale (MELASQOL) for Brazilian Portuguese persons 
revealed marked emotional impact, 94.11% of patients reporting feeling bothered, 
64.71% frustrated/embarrassed, and 52.94% depressed due to their skin condition (Ikino, 
Nunes, Silva, Fröde, & Sens, 2015).  
 
Dominguez et al., using the Spanish-language version of MELASQOL, 
demonstrated that the most affected areas were social life and well-being, with higher 
scores observed in patients with less years of formal education. Interestingly, the 
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MELASQOL score only has a moderate correlation with Melasma Area Severity Index 
(MASI), a measure of clinical disease severity (Dominguez et al. 2006). 
 
Treatment of melasma is challenging and often times disappointing to both patient 
and physician. Patient education regarding sun protective measures is extremely 
important for achieving better results. Triple combination products containing 
hydroquinone, retinoid, and a fluorinated steroid continue to be first line treatment. Other 
first line treatment includes hydroquinone in different concentrations, azelaic acid, and 
other topicals that work within the melanin synthesis pathway such as ascorbic acid, 
mequinol, and kojic acid. In addition, second line therapies include chemical peels and 
oral treatments and third line therapy include laser and light devices (Sheth & Pandya, 
2011a). 
 
New treatment modalities have shown variable but promising results for the 
treatment of melasma. Tranexamic acid, a plasmin inhibitor and lysine analog, available 
in oral, topical, and intradermal injections seems to be an effective modality. Shin et al. 
sought to evaluate efficacy of low-fluence QS Nd:YAG with oral tranexamic acid in 48 
Korean woman and found that subjects treated with tranexamic acid had greater MASI 
score reduction (Shin et al. 2013). In another study, oral tranexamic acid was used for 6 
months with gradual improvement of melasma lesions evaluated by physician 
assessment, patient satisfaction, and reduction of MASI score (Wu et al. 2010).  
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Novel therapies are under investigation for treatment of melasma. Metformin, an 
antidiabetic drug, has been shown to reduce melanin content in vitro and in vivo by 
decreasing cAMP levels; cAMP has an essential role in melanin synthesis (Lehraiki et al. 
2014). Another investigational therapy is omeprazole, a gastric proton pump inhibitor, 
which applied topically to UV-irradiated human skin demonstrated reduction in pigment 
levels after 3 weeks when compared to untreated controls. The hypothesis is that 
omeprazole may block melanogenesis by interfering with an alternative ATP7A, a copper 
transport P-type ATPAse, needed for copper acquisition by tyrosinase; therefore, 
reducing melanogenesis and increasing tyrosinase degradation (Matsui et al. 2015).  
 
 
2.4.2 Post-inflammatory Hyperpigmentation 
Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that is 
considered to be a normal biologic response to cutaneous injury or inflammation. 
Multiple skin disorders may result in PIH including acne vulgaris, allergic contact 
dermatitis, lichen planus, atopic dermatitis, psoriasis, and trauma among many others 
including cosmetic interventions (Halder, Nandedkar, & Neal, 2003). 
 
Although PIH affects all skin types, it is more common and/or noticeable in 
darker skinned individuals. There is no gender predilection. In a prospective study on 
prevalence of acne related PIH, it occurred in 60% of subjects (Abad-Casintahan et al. 
2016). PIH was also the second most common reason for dermatology visits in African 
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Americans individuals (Alexis, Sergay, and Taylor 2007), and dyschromia was the 11th 
reason for dermatological visits among all skin types in a list of top 20 dermatological 
conditions (Wilmer et al. 2014). 
 
The pathogenesis of PIH is thought to be secondary to stimulation of epidermal 
melanocytes by inflammatory mediators and cytokines from the inflammation site, which 
leads to an increase in synthesis and transfer of melanin to the neighboring keratinocytes, 
resulting in epidermal melanosis. Additionally, inflammation may cause disruption of the 
basal layer and release of melanin into the underlying dermis. The melanin is 
phagocytized by macrophages, now melanophages, resulting in dermal melanosis, also 
known as pigmentary incontinence (Tomita, Maeda, and Tagami 1989).  
 
PIH manifests as hyperpigmented macules and patches varying in sizes, 
distributed on site of skin injury or trauma. The color varies from tan to dark brown 
depending on the location of pigment. A blue-gray appearance is observed when pigment 
is located within the dermis (Davis and Callender 2010). PIH may take several months to 
years to fade and this likely depends on a variety of factors including skin type, intensity 
of inflammation, and sun exposure habits (Vashi & Kundu, 2013). 
 
Post-acne hyperpigmentation index (PAHPI) is a recent validated instrument 
developed by Savory et al. to help assess clinical severity and treatment efficacy in 
patients with PIH from acne (Savory et al. 2014). 
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 A single study evaluating response to treatment efficacy and safety of salicylic 
acid peels and the impact of post-inflammatory hyperpigmentation on patients’ quality of 
life reported a DLQI of 8.4 in a small sample of patients (Joshi et al. 2009). 
Prevention and treatment of underlying skin disorders is imperative in all patients 
presenting with PIH, especially in those with darker skin types. After treating the cause of 
PIH, the first line therapy are topical lightening agents such as those used for melasma, if 
no improvement after 8–12 weeks, second line therapies include chemical peels and 
laser/ light therapy (Davis and Callender 2010). 
 
 
2.4.3 Solar Lentigines  
Solar lentigines (SL) are benign hyperpigmented macules distributed over areas of 
chronic sun-exposure such as the face, dorsal hands, and forearms. They typically occur 
in later years of life but can appear at a younger age after acute UV exposure. (Bolognia, 
Jorizzo, and Schaffer 2012). Although more common in Caucasians and Asians, it is also 
seen in Fitzpatrick skin types III and IV (Monestier et al. 2006). The incidence is high 
among caucasians, affecting 90% of indivuduals over 50 years of age (J P Ortonne 1990).  
 
Clinically, solar lentigines are characterized by well-defined, dark-brown or tan 
macules with irregular borders, ranging in size from a few mm to over 1 cm. They are 
considered a sign of photoaging and usually do not fade with time (Bolognia, Jorizzo, and 
Schaffer 2012).  
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 It is without a doubt that UV radiation plays a role in the pathogensis of SL. The 
exact mechanism by which UV induces pigmentation in SL is still under debate. 
Watanabe proposed that chronic UV exposure leads to degeneration of basal cell 
keratinocytes. The damaged keratinocytes are then segregated to the upper dermis and 
later phagocytosed by poorly stimulated macrophages that lack proper migration and 
digestive abilities, resulting in the pigmentary changes noticed clinically. Moreover, 
upregulation of genes involved in the inflammatory response, melanin production, and 
fatty-acid metabolism suggest the mutagenic effect of repeated UV exposure in the 
pathogenesis of solar lentigines (Aoki et al. 2007).  
 
On histopathologic examination, findings include hyperpigmentation of basal 
layer with elongation of rete ridges and a mild increase in melanocytes on a background 
of solar elastosis. (Byrom et al. 2016).  
 
There are very few studies available in the literature evaluating the impact of 
lentigines and other facial hyperpigmentations besides melasma. One study evaluated the 
prevalence of pigmentary disorders and its impact on quality of life in 140 caucasian 
patients. Among those studied, 74.3% had the diagnosis of lentigo, of which 47.3% stated 
they they were self-conscious about their skin appearance (A. Taylor et al. 2008). 
 
Several effective treatment modalities are available including tretinoin, 
cryotherapy, chemical peels, and/or laser therapy.  The best therapeutic response is 
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typically seen with laser therapy (Ortonne et al. 2006). Although solar lentigines  are 
benign, they are a sign of photodamage, which may indicate an increased risk for the 
development of skin cancers. Therefore, patient education about regular use of sunscreen 
and sunprotective measures are an important part of treatment. 
 
 
2.4.4 Seborrheic Keratosis and Dermatosis Papulosa Nigra 
Seborrheic Keratosis (SK) is a common benign skin tumor that affects both men 
and women. Prevalence increases with age. It presents as single or multiple well 
demarcated, skin-colored to hyperpigmented, “stuck-on” papules that are typically seen 
on the back, chest, and extremities. Despite commonly being located on sun covered 
areas, sun exposure may be associated with earlier onset and higher frequency of 
seborrheic keratosis (Yeatman, Kilkenny, and Marks 1997). Although the etiology is 
unknown, it appears to have a familial tendency with an autosomal dominant pattern of 
inheritance.  
 
Dermatosis Papulosa Nigra (DPN) is a variant of SK that presents as small 
hyperpigmented smooth papules commonly observed in in darker skin types, especially 
African Americans and Afro-Caribbeans. It is more common in women and rarely 
observed in children.  DPNs have an earlier onset and may even appear during 
adolescence. Lesions typically increase with age. SK and DPN are mostly asymptomatic; 
however, they may become pruritic and irritated. Treatment is not required unless for 
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cosmetic reasons (Bolognia, Jorizzo, and Schaffer 2012).  
 
 
2.4.5 Lichen Planus Pigmentosus 
Lichen planus pigmentosus (LPP) is a chronic acquired disorder of 
hyperpigmentation classified as a variant of lichen planus that usually occurs in young to 
middle aged darker skinned individuals, especially those of Indian, Latin American, and 
Middle Eastern descent (Al-Mutairi and El-Khalawany 2010). 
 
LPP is characterized clinically by oval to round gray-brown macules that may 
coalesce into patches on sun-exposed areas, commonly the face and neck and/or flexures 
(lichen planus pigmentosus inversus). Lesions are usually symmetric but can present 
unilaterally. They are often asymptomatic but can occasionally be pruritic. In contrast 
with erythema dyschromicum perstans (EDP), there is no previous history of an 
erythematous border.  Patients may present with classic lichen planus lesions in other 
areas, and mucosal involvement has been reported (Al-Mutairi and El-Khalawany 2010).  
 
Although the pathogenesis remains unknown, application of topical 
photosensitizers, such as mustard and amla oils along with sun exposure are possible 
culprits (Kanwar et al. 2003). On histology, main features of LPP include epidermal 
atrophy, vacuolar degeneration of basal layers, melanin incontinence, and presence of 
dermal melanophages.  
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 There were no studies evaluating health-related quality of life (HRQoL) in 
patients with LPP. The disease course is unpredictable with periods of remission and 
exacerbations. Treatment options include topical steroids, calcineurin inhibitors, skin 
lightening agents, and chemical peels. Treatment with low-fluence 1064 nm Q-switched 
neodymium-doped yttrium aluminum garnet laser in combination with tacrolimus 
(calcineurin inhibitor) has been reported (Vashi and Kundu 2013). 
 
2.4.6 Maturational Hyperpigmentation 
Maturational hyperpigmentation is a descriptive term that refers to darkening of 
sun-exposed and mature skin, occurring in those with darker skin tones, especially skin 
phototypes V and VI. This recently described, yet likely common acquired 
hyperpigmentatinon, was first reported by Dr. Melvin Alexander as an unusual pattern of 
facial hyperpigmentation, involving malar and zygomatic facial areas, which often had 
ill-defined borders with fading into the patients’ natural skin color (N. Vashi, Kundu, and 
Larocca 2014). 
 
Maturational hyperpigmentation is characterized clinically by darkening of the 
lateral forehead, temples, cheeks, and also dorsal hands and feet in areas of sun-exposure.  
Treatment options include the same principles as those used for both melasma and post-
inflammatory hyperpigmentation including sun protective measures and topical 
lightening agents, antioxidants, microdermabrasion, chemical peels, and/or laser and 
light-based therapy (Vashi and Kundu 2013). 
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2.4.7 Acanthosis Nigricans 
Acanthosis nigricans (AN) is a common acquired disorder characterized by 
symmetrical hyperchromic plaques with a velvety texture typically seen on the neck, 
axilla, infra-mammary folds, and groin. AN is more common in obese adults but may 
appear at any age. AN is estimated to affect 20% of the US population (Kong et al. 2010) 
and appears to have a higher prevalence in African American (13.3%) and Hispanic 
(5.5%) population (Gilkison and Stuart 1992). 
 
The pathogenesis is not fully understood. The hypothetical mechanism is that 
elevated insulin concentrations stimulate the proliferation of keratinocytes by binding to 
insulin-like growth factor-1 receptors present on keratinocytes, resulting in the clinical 
and histological finding of hyperkeratosis and papillomatosis (Hermanns-Lê, Scheen, and 
Piérard 2004).  
 
AN may be a cutaneous marker for internal disease including insulin resistance 
and polycystic ovary syndrome (PCOS). Rarely, development of extensive AN, including 
involvement of the  oral mucosa and palms in non-obese individuals (N., J., and J. 2013), 
can be suggestive of an internal malignancy. The proposed pathogenesis of malignant 
acanthosis nigricans is tumor secretion of transforming growth factor α (TGF-α) in the 
circulation, which stimulates keratinocyte proliferation (Koyama et al. 1997).  
 
The clinical presentation consists of darkening and thickening of skin of the 
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axilla, groin and nape of neck, and less so on the face and other flexural areas. There are 
8 types, obesity-related or pseudo AN, syndromic, benign, malignant, acral, unilateral, 
secondary to medication, and multifactorial or mixed type (Puri 2011). Mutation in 
fibroblast growth factor receptor gene (FGFR), FGFR2, and FGFR3 has been associated 
with familial AN (Ichiyama et al. 2016). 
 
Histology reveals hyperkeratosis, papillomatosis, a variable degree of acanthosis 
without increase in melanocyte density, and melanin deposition. The dark appearance is 
due to hyperkeratosis and not an increase in the melanotic component (Murphy-
Chutorian, Han, and Cohen 2013). 
 
There is no information on health-related quality of life and AN. The goal of 
therapy is to treat the underlying condition. Weight reduction may significantly improve 
obesity associated AN, and discontinuation of an offending drug may also help in 
medication related AN. Topical therapy includes keratolytic agents, tretinoin, and 
chemical peels. 
 
 
2.4.8 Periorbital hyperpigmentation 
Periorbital hyperpigmentation (POH), also known as “dark circles” by patients is 
a very common dermatological complaint that affects all skin types, although more 
common in darker-skinned individuals.  There is limited data on prevalence of POH, one 
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study conducted in India estimates the prevalence to be 30.76%, being slightly more 
common in women than men (P. B. Sheth, Shah, and Dave 2014). 
 
Etiopathogenesis is complex involving multiple factors.  POH can be divided into 
primary and secondary types. Primary type, also called idiopathic cutaneous 
hyperchromia of the orbital region (ICHOR), refers to skin darkening around the eyes 
without any systemic or local cutaneous disorders. Usually this form has an early onset, 
being observed in childhood and may progress during life. It has been suggested that this 
could in fact be an extention of pigmentary demarcation lines rather than a distinct 
condition (Malakar et al. 2007). 
 
Secondary type is called periorbital hyperpigmentation (POH). Secondary POH  
can appear as a result post-inflammatory hyperpigmentation due to atopy or allergic 
contact dermatitis, genetic background, increased skin pigmentation, hypervascularity, 
edema, and aging (Sarkar et al. 2014). The inheritance  patterns of the genetic or 
constitutional form of POH is unclear, it may be autosomal dominant with different 
expression among family members (N. Vashi, Kundu, and Larocca 2014).  
 
Individual face anatomy and the natural aging process contributes to a hollow and 
shadow appearance observed in older patients, due to the formation of a  deeper tear 
trough and protrusion of infraorbital fat with aging. In addition, skin thinning, laxity, 
periorbital edema, and increased cutaneous vasculature may in combination worsen the 
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clincial appearance of the periorbital region (Alsaad and Mikhail 2013). Environment and 
lifestyle such as lack of sleep, sun exposure, nutritional status, drug intake, and hormonal 
causes are contributing factors for POH (Roberts 2014). 
 
Huang et al. proposed a classification of dark circles based on clinical 
presentation and evaluation by wood’s lamp and ultrasound. Dark eye circles were 
classified into 4 patterns: pigmented type, presenting as a brown hue without pink on 
bluish color; vascular type, appearing as a blue, pink or purple hue; structural type, 
appearing as a shadow due to face contour and disappears after front light ilummination; 
and mixed type, which combines one or more of the described features. They found that 
the most common type was mixed (78%), followed by vascular (14%), pigmented (5%), 
and structural (3%) (Huang et al. 2014). 
 
On histology, biopsy of lesional skin showed dermal melanocytes (Watanabe, 
Nakai, & Ohnishi, 2006), and larger blood vessels without hemosiderin deposition 
(Graziosi et al. 2013). POH may have a negative impact on patient quality of life.  
Patients complain of having  a tired, sad, or stressed appearance. Treatment of periorbital 
hyperpigmentation is complex and therapy should be tailored to a patient’s presentation 
and individual needs. Several treatment modalities have been reported, including 
hydroquinone, vitamin C, chemical peels, lasers, injection of autologus fat or hyaluronic 
acid fillers, with variable success (Roberts 2014).  
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2.4.9 Erythema Dyschromicum Perstans 
Erythema dyschromicum perstans (EDP) or ashy dermatosis (dermatosis 
cinecienta) is a chronic asymptomatic disorder characterized by gray-brown macules and 
patches on both sun-exposed and sun protected areas of the trunk, arms, and face 
(Ramirez and Lopez Lino 1984). It usually affects young adults and children. Even 
though EDP can affect all racial and ethnic groups, it is more common in Latin American 
and Asian populations (Chang et al. 2015). 
 
The etiology of EDP is unclear; however, a possible immune-mediated reaction to 
an unknown trigger in genetically susceptible patients has been proposed (Piquero-Martin 
et al. 1989). Reported triggers include medications (penicillin, benzodiazepines), 
radiographic oral contrast, pesticides, and infestations.  It has been associated with 
endocrinopathies, vitiligo (Henderson, Tschen, and Schaefer 1988), and HIV. 
Additionally, in Mexican mestizo patients HLA-DR4 may be a risk factor (Correa et al. 
2007). 
 
EDP presents as relatively well-defined, blue-black to ash-gray macules and 
patches distributed symmetrically on the trunk, neck, upper extremities, and face. It may 
have a discrete, raised erythematous border. Mucosal involvement is uncommon  (Vashi 
& Kundu, 2013). 
 
Histologically, active lesions of EDP show vacuolar degeneration of the basal 
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layer, papillary dermal edema, and a lymphocytic infiltrate. Older or inactive lesions 
show pigment incontinence and dermal melanophages without inflammation (Chang et 
al. 2015). 
 
There are many reported therapeutic options to treat EDP; however, most are 
ineffective. Topical lightening agents and steroids are usually not helpful. Oral 
medications such as corticosteroids, griseofulvin, isoniazid, and antimalarials have been 
reported.  In two small case series, dapsone (Bahadir et al. 2004) and clofazimine showed 
good treatment response (Piquero-Martin et al. 1989). Tacrolimus 0.03% applied twice 
daily showed improvement in about 57% of patients in a prospective study with 13 
subjects (Al-Mutairi and El-Khalawany 2010). 
 
 
2.4.10 Exogenous Ochronosis  
Exogenous Ochronosis (EO) is a rare and poorly understood cause of cutaneous 
hyperchromia. It is characterized by blue-black or black-brown macules coalescing into 
patches, distributed symmetrically over the infraorbital and zygomatic regions. The 
incidence of EO is unkown, with the majority of cases reports being from Africa (Burke 
and Maibach 1997) and only few reported in the United States. Aside from Africa, the 
worldwide incidence appears low. This could be attributed to under-reporting or 
misdiagnosis with clinically similar conditions (Tan 2010). 
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Although the reason for this feared hyperchromia remains elusive, it is believed 
that it results from prolonged use of topical agents that include hydroquinone, resorcinol, 
phenol, mercury, quinine injections, antimalarials, and /or picric acid.  The most accepted 
hypothesis is that EO results from inhibition of the enzyme homogentisic acid oxidase 
(HGOA) by hydroquinone containing compounds, leading to accumulation of 
homogentisic acid, which is then polarized to form the ochronotic pigment deposited in 
the dermis (Ladizinski, Mistry, and Kundu 2011). 
 
EO is characterized clinically by asymptomatic brown-gray or blue-gray lesions 
on sites of contact and sun exposure, most often of the face and neck and less often the 
extensor surfaces. Exogenous ochronosis can be classified into 3 clinical stages: (1) 
erythema and mild pigmentation; (2) hyperpigmentation, black colloid milium (“caviar-
like” lesions), and scant atrophy; (3) papulo-nodular lesions, with or without 
inflammation (Dogliotti and Leibowitz 1979).  
 
Histologically, exogenous ochronosis reveals the classically yellow-brown, 
banana shaped deposits in the papillary dermis with an overlying normal epidermis. In 
early stages, subtle changes including basophilia, homogenization, swelling of the 
collagen bundles, and altered texture and arrangement of elastic fibers similar to solar 
elastosis are observed (Chowdary, Mahalingam, and Vashi 2014). Late lesions may 
present with degeneration of ochronitic pigment forming a colloid millium (Findlay, 
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Morrison, and Simson 1975) and rarely formation of sarcoid-like granuloma has been 
reported (Dogliotti and Leibowitz 1979). 
 
Dermoscopy and reflectance confocal microscopy are non-invasive tools that may 
be helpful to differentiate EO from other common hyperpigmentation disorders including 
melasma, especially in patients who prefer to avoid skin biopsy. Dermoscopy findings of 
EO include blue-gray amorphous areas obliterating follicular openings but not 
surrounding them, (Charlín et al. 2008) a diffuse brown background and small, thin 
annular brown-gray globules around the follicular openings may be observed. In contrast, 
melasma has a brown reticular pattern with a light brown background and follicular 
sparing (Gil et al. 2010). 
 
The reflectance confocal microscopy (RCM) features of EO are well-defined, 
dark round to oval spaces located next to follicles and banana-shaped structures in the 
papillary dermis (Gil et al. 2010). 
 
EO has notoriously been extremely difficult to treat with just few case reports 
illustrating treatment options of trichloroacetic acid, cryotherapy, retinoic acid, and low 
potency topical corticosteroids, and satisfactory options of dermabrasion, CO2 laser 
(Kanechorn-Na-Ayuthaya et al. 2013), chemical peels, q-switched laser (Bellew and 
Alster 2004), and intense pulsed light (IPL) (Gil et al. 2010).  Results, overall, have 
typically not been uniform or consistently successful.  Early diagnosis and patient 
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education regarding long term use of hydroquinone compounds and use of hydroquinone 
sparing agents are important measures in order to prevent this difficult to treat condition. 
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CHAPTER THREE: METHODOLOGY 
 
3.1 Research Design 
This is a cross-sectional study conducted to evaluate the impact of skin 
hyperpigmentation disorders on patients’ health-related quality of life and patients’ 
knowledge, attitudes, and practices towards skin hyperpigmentation disorders.  The study 
was approved by the Boston University Institutional Review Board (IRB) under protocol 
number H-33375. This study aims to answer the following questions: 
1. How does hyperpigmentation affect patients’ quality of life and what are patients’ 
knowledge, beliefs, and attitudes regarding these disorders? 
2. Do assessments of clinical disease severity predict quality of life? 
3. What are the factors associated with a higher impact on quality of life measures? 
4. What are the factors associated with patients’ knowledge of their diagnosis? 
  
 
3.2 Sample 
The study was conducted on 298 consenting adult patients with a skin 
hyperpigmentation disorder who sought dermatological care at Boston Medical Center 
(BMC) or East Boston Neighborhood Health Center (EBNHC) from February of 2015 to 
March of 2016. Subjects under the age of 18 and those unable or unwilling to complete 
the questionnaire were excluded.  No identifying information was collected, and only 1 
visit was required to complete the survey and the clinical examination. Inclusion criteria 
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can be found in appendix V. 	
Eligible patients who spoke English, Spanish, or Portuguese were verbally asked 
if they were willing to participate in a onetime questionnaire about their skin disorder. 
Patients who expressed willingness to participate received a detailed informed consent 
(Appendix I) explaining the study.  		
3.3 Data Collection 
Information about patients were collected in two parts; a self-administered survey 
and a clinical examination performed by a trained dermatologist. For the first part, those 
who agreed to participate after reading the informed consent were given the survey — a 
paper-based questionnaire — in their preferred language. A study member was available 
to answer questions related to the survey during the entire duration needed to complete 
the survey, and at times helped patients with poor reading skills to complete the survey. 
The self-administered survey comprised 3 domains. The first domain collected 
information about demographic characteristics such as age, gender, country of birth, 
primary language spoken, occupation, race/ethnicity, marital status, and educational 
level. The second domain incorporated 22 non-validated multiple-choice questions 
regarding patients’ knowledge about etiology, use of sunscreen, and sun protective 
behaviors. Patients were also asked if family members had a similar condition, and about 
their feelings towards their skin condition, skin health practices, and previous treatments. 
The third domain included the following quality of life measurement tools: the 
Dermatology Life Quality Index (DLQI), and the Skin Discoloration Impact Evaluation 
		
35 
Questionnaire (SDIEQ). The two measurement tools are detailed in appendix IV and V, 
respectively. 
 
The DLQI is the first validated dermatology-specific health-related quality of life 
questionnaire (Finlay and Khan 1994). It is composed of 10 questions covering 6 
different domains of quality of life, including symptoms and feelings related to daily 
activities, leisure, work and school, personal relationships, and treatment over the past 
week. Subjects were asked to tick a box that best described their answer. The response to 
each question ranged on a Likert scale from 0= not at all, 1= a little, 2= a lot, to 3= very 
much. Total score ranges from 0 (no impairment of quality of life) to 30 (maximum 
impairment). To translate DLQI to a more practical clinical interpretation about patients 
view of overall impairment on skin-related quality of life, the 5 DLQI bands score 
proposed by Hongbo et al. were used. DLQI scores 0 to 1=no effect on patient's life, 
DLQI scores 2 to 5=small effect on patient's life; DLQI scores 6 to 10=moderate effect 
on patient's life; DLQI scores 11 to 20=very large effect on patient's life; DLQI scores 21 
to 30=extremely large effect on patient's life (Hongbo et al. 2005). 	
The SDIEQ is a five-item, non-validated, brief health-related quality of life 
questionnaire (A. Taylor et al. 2008). It is composed of five items graded on a Likert 
scale from 0= not at all, 1= a little, 2= a lot to 3= very much. A total score ranges from 0 
(no impairment of quality of life) to 15 (maximum impairment) (Appendix V). (A. Taylor 
et al. 2008) (Balkrishnan et al. 2003). 	
After completing the survey, a physician trained in dermatology proceeded with a 
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clinical examination and further diagnostic processes. In addition to the structured 
dermatological clinical examination, careful collection and documentation of information 
was performed in two subdomains: a general information subdomain including diagnosis, 
skin type, and visit type, and a diagnosis-specific subdomain. The diagnosis specific 
subdomain was performed for patients with melasma and post acne hyperpigmentation. 
For those diagnosed with melasma, the modified Melasma Area Severity Index (MASI), a 
reliable and validated tool, was used (Appendix VI) [(Kimbrough-Green et al. 1994)]. A 
total MASI score was obtained along with a clinical determination of melasma pattern.  
The MASI score is calculated by a subjective assessment of three factors: area (A) of 
involvement, darkness (D) and homogeneity (H). The area of involvement of the 
forehead, right malar region, left malar region and chin corresponding, respectively, to 
30%, 30%, 30% and 10% of total face. Each of these four areas is given a numeric value 
of 0 to 6 (0= no involvement; 1= < 10 %; 2=10–29%; 3=30–49%; 4= 50–69%; 5= 70–
89% and 6= 90–100%). Darkness and homogeneity are rated on a scale from 0 to 4 (0= 
absent; 1= slight; 2=mild; 3=marked; 4=maximum). The total score ranges from 0 to 48. 
Recent literature by Pandya et al. has suggested the elimination of the homogeneity 
assessment which was followed in this study (Pandya et al. 2011). Hence, modified 
MASI score was calculated as follows: forehead 0.3 (D)(A) + right malar 0.3 (D)(A) + 
left malar 0.3 (D)(A) + chin 0.1 (D)(A).  To increase the validity of our clinical 
evaluation, wood’s light examination was performed to help identify the possible location 
of pigment deposition. In epidermal melasma, lesions are enhanced with wood’s light, 
whereas in dermal melasma, lesions are not. When some areas are enhanced and other are 
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not, a mixed appearance is noted. Often times, wood light examination does not help 
distinguish lesion from normal especially in darker skin types, and this pattern is known 
as indeterminate or inapparent (N. P. Sanchez et al. 1981).  
 
 For patients that were diagnosed with post-acne hyperpigmentation, based on 
clinical examination and history, the Post Acne Hyperpigmentation Index (PAHPI) 
(Appendix VII) was calculated. The PAHPI is a validated scoring method developed by 
Savory et al. It measures the clinical severity of post-inflammatory hyperpigmentation 
from acne. It consists of three domains: size, intensity, and number of lesions. Each 
variable is assigned different weights, with lesion size and darkness being assigned 
higher weights. The sum of the three variables ranges from 6 to 22 (Savory et al., 2014). 
For all other disorders of hyperpigmentation, the body location and body surface area was 
obtained. No additional scoring method was used for any other diagnosis. 
 
 
3.4 Statistical Analysis 
Study data were collected and managed using Research Electronic Data Capture 
(REDCap) tool (Harris et al. 2009). REDCap is a secure, web-based application designed 
to support data capture for research studies. Data entry was performed by co-investigator 
Mayra Buainain de Castro Maymone.  Excel sheets were generated through REDCap and 
exported to STATA. Statistical analyses were performed using STATA/SE 13.0. 
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Descriptive statistics for general demographic, clinical characteristics, and general 
attitudes and knowledge regarding hyperpigmentation disorders were generated and are 
reported in separate tables. Given that PIH and melasma were the 2 most common 
diagnoses, a new variable for diagnosis was constructed to reflect those diagnosed with 
PIH, melasma, and those with other hyperpigmentation disorders, being grouped under 
one category. For purposes of this thesis, “other hyperpigmentation disorders” refers to 
diagnoses other than PIH or melasma found in this sample. Chi-square and Fisher exact 
tests were used to examine significant differences pertaining to descriptive characteristics 
as broken down by the three categories of diagnosis: PIH, melasma, and others. 
 
A correlation matrix was calculated for the association between measures of 
quality of life, and measures of disease severity was assessed using Spearman rho 
correlation.  DLQI score, MASI, PIH, and SDIEQ scores were mathematically 
transformed to resemble a normal distribution.  
 
A bivariate analysis with one-way analysis of variance and post-hoc test was 
performed to describe the magnitude of hyperpigmentation disorders as broken down by 
PIH, melasma, and others on patients’ quality of life as measured by DLQI. Mean scores 
for DLQI for every respondent was generated by dividing the total score by the number 
of questions for descriptive purposes, while the effect of the total DLQI was modeled in 
the bivariate model. The DLQI total scores were transformed arithmetically to closely 
resemble a normal distribution and satisfy the assumption for ANOVA. 
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Two multivariate models were constructed: a logistic multinomial regression and a 
multiple regression model. A logistic multinomial regression was performed to 
determine factors associated with higher odds of patients’ knowledge of their actual 
diagnosis as determined by the clinician. Patient’s knowledge of their diagnosis variable 
was constructed by using information from both the self-administered survey and the 
clinical examination. Those patients whose reported diagnosis matched the clinical 
diagnosis made by the dermatologist were coded as “yes”, while those who did not were 
codes as “no”. The model was adjusted to the following confounders: level of education 
(coded into three categories; lower/elementary school or middle school, high school 
diploma, and college or graduate degree), age (coded in two categories; younger or equal 
to 45 years of age and older than 45), visit type (coded in two categories; first visit or a 
follow-up visit), disease duration (coded in three categories; those who had their 
condition for up to 12 months, for up to 5 years, and for up to 15 years or longer), and 
use of sunscreen (coded in three categories; currently using sunscreen, not using 
sunscreen, and those who do not know).  The second model was a multiple regression 
model performed to determine factors associated with higher DLQI scores. The model 
was adjusted to the following potential confounders: clinical diagnosis, disease duration, 
visit type, age, use of sunscreen, and accurate knowledge of the diagnosis. Gender was 
not included as a confounding factor because given the gender imbalance in the dataset, 
the results would likely be skewed away from the null. We also did not include race, 
language, and skin-type as all of these were found to highly correlate with each other 
and education. Controlling variables in our model was done based on a “stepwise” 
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method as there is very limited prior information from the literature. We kept the 
variables that made up the cut point of (0.1) significance level in the model. We then re-
arranged the order of introducing these variables to the model and chose to perform a 
“forced entry” regression method, as the stepwise regression method is not 
recommended due to its many limitations (Field 2009). We inserted the variables in the 
model based on our theory of their relative contribution on patients’ quality of life. We 
chose to include education rather than race or language because we were interested in 
making inferences about modifiable attributes for patients and for informing policies. 
All assumptions for logistic and multiple regression were examined. To meet the 
assumptions, DLQI scores were converted to square roots to closely resemble a normal 
distribution and predictors that were found to be associated were removed from the 
model. 
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CHAPTER FOUR: RESULTS 	
	
4.1 Descriptive Statistics 
4.1.1 Socio-demographic characteristics of study participants  
A total of 298 patients completed the questionnaire. The mean age was 41 years 
(SD ± 12.39).  The majority of patients was female (268, 90%) and identified themselves 
as white (121, 50%) and Hispanic (140, 51%). Two hundred and thirteen (72 %) of 
patients were not U.S. born, and the top five countries of origin were U.S., El Salvador, 
Colombia, Dominican Republic, and Guatemala. The reported primary language spoken 
was English in (119, 41%), followed by Spanish 113 (39%) and Portuguese (30, 10.3%). 
Most of the patients were single (142, 48.8%), employed (197, 70.68%), and had a high 
school diploma (95, 32.8%), this being the most common highest level of education. 
Detailed demographic characteristics are presented in Table 4.  
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 																																*	Sample	size	may	vary	due	to	missing	data.		
Table 4. Basic demographic characteristic of the study population (n=298) 
	  
Characteristic n  (%) 
Age    
(18–25) 26 (08.72%) 
(26–35) 87 (29.19%) 
(36–45) 82 (27.52%) 
(46–55) 63 (21.14%) 
(≥ 56) 40 (13.42%) 
 
Gender     
Female  268 (89.58%) 
Male  30 (10.42 %) 
 
Race (n=238)*   
White 121 (50.48%) 
African American 92 (38.66%) 
Asian 23 (09.66%) 
Native American 2 (00.84%) 
 
Ethnicity (n= 274)*   
Hispanic or Latino 140 (51.09%) 
Not Hispanic or Latino 134 (48.91%) 
 
Marital status (n=291)*   
Single 142 (48.80%) 
Married 104 (35.74%) 
Separated 10 (03.44%) 
Widowed 8 (02.75%) 
Divorced 15 (05.15%) 
Living in common law 12 (04.12%) 
Occupation (n=278)   
Working  197 (70.68%) 
Not working 81 (29.14%) 
 
Education (n=291)   
Lower/elementary school 28 (09.62%) 
Middle school 40 (13.75%) 
High school 95 (32.65%) 
College 72 (25.34%) 
  Graduate school 54 (18.56%) 
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4.1.2 Basic clinical characteristic 
Among those diagnosed with a disorder of hyperpigmentation, melasma was the most 
common diagnosis, affecting 50% of patients, followed by post-inflammatory 
hyperpigmentation (33%), lentigines (7.4%), dermatosis papulosa nigra (3.4%), 
seborrheic keratosis (3.4%), and lichen planus pigmentosus (2.7%). The frequency of 
various hyperpigmentation disorders diagnosed in the study participants can be found in 
Table 5. 
Table 5. Diagnosis of hyperpigmentation conditions among study participants. 
Diagnosis (n=298) n (%) 
Melasma 149 (50%) 
Post-inflammatory hyperpigmentation 
     PIH due to acne 
99 (33.2%) 
51 (51%) 
Lentigines 22 (7.4%) 
Dermatosis papulosa nigra 10 (3.4%) 
Seborrheic keratosis  10 (3.4%) 
Lichen planus pigmentosus 8 (2.7%) 
Maturational hyperpigmentation 7 (2.4%) 
Acanthosis nigricans 6 (2.0%) 
Periorbital hyperpigmentation 5 (1.7%) 
Erythema dyschromicum perstans 3 (0.1%) 
Macular amyloidosis 2 (0.7%) 
Exogenous Ochronosis 1 (0.3%) 
Drug induced hyperpigmentation 1 (0.3%) 
Melanocytic nevi 1 (0.3%) 
Nevus of Ota 1 (0.3%) 
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Basic clinical characteristics are presented in Table 6.   
 
The most common Fitzpatrick skin phototypes were III and IV (38.6% and 29.5%, 
respectively). Patients with Fitzpatrick skin phototypes IV were more likely to be 
diagnosed with melasma (p=0.003), while those with skin phototypes V and VI were 
more likely to be diagnosed with PIH (p=0.001 & 0.004, respectively). Patients 
diagnosed with melasma were more likely to have the disorder for up to 5 years and those 
with PIH were more likely to have it for >10 years (p=0.037 and 0.046, respectively).  
Among those patients diagnosed with melasma (50%), the most common clinical 
pattern was centrofacial (49%), followed by malar (26.9%), combined (22.1%), and body 
(1%). Wood’s light evaluation was performed in 99 patients; the most common pattern 
was mixed 59 (59.6%), followed by epidermal 42 (42.4%), inapparent 2 (2%), and 
dermal 1 (1.1%).  The mean modified MASI score was 5.3 (SD ± 3.46). Use of birth 
control was reported by 151 patients, and the most common methods were oral 
contraceptives (62.3%), Mirena/Skyla® IUD (13.9%), Copper IUD (12.6%), Depo-
Provera® (7.9%), etonogestrel implant -Implanon® (6.6%).  Ninety-seven (47.5%) of those 
who were diagnosed with melasma were found to be currently using birth control while 
56 (27.45%) and 51 (25%) among those who were diagnosed with PIH and other 
hyperpigmentation disorders, respectively. This was found to be statistically significant at 
p value 0.042. There was no significant association between use of thyroid medication 
and the development of any type of hyperpigmentation disorder evaluated in our study.  
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Table 6. Basic clinical characteristics of the study population 
	
Attribute n¤	(%)	 Melasma  
Mean /n(%) 
PIH 
Mean 
/n(%) 
p 
value⌘	
Skin type (n=295*) 
 
I 0 0 0 - 
II 16   (05.42%) 6   (85.71) 1   (14.29) 0.243 
III 87   (29.49%) 45 (64.29) 25 (35.71) 0.188 
IV 114 (38.64%) 64 (69.57) 28 (30.43) 0.003 
V 52   (17.63%) 10 (27.03) 27 (72.97) 0.000 
VI 26   (08.81%) 4   (23.53) 13 (76.47) 0.004 
 
Duration of symptoms (n=241*) 
 
 
 
Up to 1 year 16   (06.64) 12 (46.15) 14 (53.85) 0.323 
Up to 5 years 101 (41.91) 47 (64.38) 26 (35.62) 0.037 
Up to 10 years 56   (23.24) 25 (56.82) 19 (43.18) 0.787 
> 10 years 20   (08.30) 14    (40.00) 21   (60.00) 0.046 
 
 DLQI(n=282*) 
 
    
No effect  55   (19.50) 12 (37.50) 20 (62.50) 0.501 
Small effect 89  (31.56) 36 (57.14) 27 (42.86) 0.990 
Moderate effect 72  (25.53) 35 (58.33) 25 (41.67) 0.816 
Very large effect 63  (22.34) 29 (53.70) 25 (46.30) 0.562 
Extreme effect 3    (01.06) 1   (33.33) 2  (66.67) 0.578 
 
SDIEQ(n=202) 
 
    
Small impact 98 (32.89) 36 (58.06) 26 (41.94) 0.772 
Medium impact 63 (21.14) 26 (50.98) 25 (49.02) 0.313 
High impact 
 
41 (13.76) 23 (62.16) 14 (37.84) 0.437 
*   Denominators might differ due to missing data. 
⌘ Generated through either chi-square test or fisher exact test whenever appropriate.	
¤ Other causes of hyperpigmentation are included in total n size calculation but not in 
chi-square or Fisher exact tests; therefore, numbers might not add up to total n.	
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Post-inflammatory hyperpigmentation was the second most common diagnosis, 
affecting 99 patients. Among those diagnosed with PIH, 51 patients had PIH related to 
acne. In order to assess the severity of post-inflammatory hyperpigmentation, we used the 
PAHPI score developed by Savory et al.  The mean PAHPI score was 10.32 (SD ±3.34). 
We arbitrarily assigned cut off points for the obtained results that ranged from a 
minimum of 6 to a maximum of 22 points: 6–10=very mild, 11–14=mild, 15–
18=moderate, and 19–22=severe post-inflammatory hyperpigmentation (PIH). Most 
patients were found to have very mild to mild disease severity. 
The overall mean DLQI was 6.56 (SD ±5.35), minimum and maximum ranges 
were 0 to 24. The mean total DLQI in those diagnosed with PIH was 7.89 (SD ± 0.61), 
melasma 6.75 (SD ± 0.45), and other hyperpigmentation disorders 4.5 (SD ± 0.55). 
Overall, 31.5% and 25.5% of patients reported small and moderate effects on quality of 
life, respectively. No significant difference between groups was found when comparing 
DLQI score bands (Table 6 and 8). The mean total score obtained in the 5-question Skin 
Discoloration Impact Evaluation questionnaire (SDIEQ) questionnaire was 6.36 ± 4.59, 
minimum and maximum ranges are 0 to 15. Overall, most patients reported a small 
impact (98, 32.8%) and moderate impact (63, 21.1%) on their quality of life (Table 6). 
 
4.1.3 Patients’ knowledge, attitudes and practices among survey participants 
Patients’ beliefs, knowledge, attitudes, and practices regarding predisposing 
factors, such as sun awareness, previous treatment, monthly expenditure on over-the-
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counter skin products, and best person to treat their skin condition are described in detail 
in Table 7. 
 
 
4.1.4 Patients’ knowledge of predisposing factors  
Our analyses demonstrated that patients diagnosed with melasma were 
significantly more likely to attribute the cause of brown spots to the sun (59.74%, 
p<0.001) and hormones (58.73%, p< 0.001) when compared with those with PIH and 
other skin hyperpigmentation disorders (Table 7). Patients diagnosed with PIH were more 
likely to attribute the brown spots to acne (68%, p <0.001). There was no statistically 
significant difference among those that attributed the cause of brown spots to genetic, 
race, or family history (Table 7). 
 
 
4.1.5 Patients’ behavior regarding sun protection and sun awareness  
Most patients 201 (69.01%) reported using lotion, cream, and/or skin products 
containing sunscreen. More than half of the patients did not know if their sunscreen was 
broad spectrum. More patients with melasma used sunscreen 107 (53.23%) when 
compared with those with PIH (46, 22.89%) and other hyperpigmentation disorders (48, 
23.88%). In contrast, those diagnosed with PIH used sunscreen less (44, 51.76%) when 
compared with patients diagnosed with melasma and other hyperpigmentation disorders. 
There was a significant difference between groups difference for this comparison (p 
<0.001) (Table 5).  
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Table 7.  General description of patients’ beliefs, attitudes, and knowledge about 
hyperpigmentation conditions 	
Attribute	 n	(%)	 Melasma		
Mean	/n(%)	
PIH	
Mean	/n%	
Other	
Mean	/n%	
p	value	
	
Attributed	cause	of	brown	spots§	Sun	 77			(26.19)	 46	(59.74)	 10	(12.99)	 21	(27.27)	 0.000	Genetic	 75			(26.04)	 27	(36.00)	 25	(33.33)	 23	(30.67)	 0.079	Hormones	 63			(22.42)	 37	(58.73)	 15	(23.81)	 11	(17.46)	 0.000	Acne	spots/rash	 91			(32.04)	 18	(19.78)	 62	(68.13)	 11	(12.09)	 0.000	Race	 102	(34.34)	 35	(34.31)	 41	(40.20)	 26	(25.49)	 0.107	Family	history	 104	(35.25)	 39	(37.50)	 35	(33.65)	 30	(28.85)	 0.610	
	
Currently	using	sunscreen	(n=291)*	Yes		 201	(69.01)	 107	(53.23)	 46	(22.89)	 48	(23.88)	 0.000	No	 		85	(26.02)	 17		(20.00)	 44	(51.76)	 24	(28.24)	 	I	don’t	know	 				5	(01.70)	 	2		(40.00)	 		3	(60.00)	 		0			(0.00)	 	
	
Sun	Protection	Factor	(SPF)	(n=210)*	10–	20	 24			(11.43)	 		7	(29.17)	 		7	(29.17)	 10	(41.67)	 0.008	21–50	 102	(48.57)	 51	(50.00)	 31	(30.39)	 20	(19.61)	 	50–100	 38			(18.10)	 26	(68.42)	 		2			(5.26)	 10	(26.32)	 	>100	 12			(05.71)	 		9	(75.00)	 		2	(16.67)	 		1		(8.33)	 	Don’t	know	 34		(16.19)	 19	(55.88)	 		7	(20.59)	 	8	(23.53)	 		
Frequency	of	sunscreen	application	(n=	209)*	Every	2	hours	 17			(08.13)	 	10	(58.82)	 		3	(17.65)	 		4	(23.53)	 0.008	2	to	3	times	a	day	 108	(51.67)	 	64	(59.26)	 17	(15.74)	 27	(25.00)	One	time	a	day	 28			(13.40)	 	15	(53.57)	 		7	(25.00)	 	6		(21.43)	Occasionally	/	almost	never	 56			(26.79)	 	19	(33.93)	 25	(44.64)	 12	(21.43)		
Broad	spectrum	(n=100)*	Yes	 39	(39.00)	 17	(43.59)	 15	(38.46)	 		7	(17.95)	 0.653	No	 		5	(05.00)	 		2	(40.00)	 		2	(40.00)	 		1	(20.00)	Don’t	know	 56	(56.00)	 27	(48.21)	 14	(25.00)	 15	(26.79)	
	
Sun-protective	measures:	wear	a	hat	(n=287)*																																																																							Rarely	or	never	 147	(51.22)	 65	(44.22)	 49	(33.33)	 33	(22.45)	 0.092	Sometimes	 83	(28.92)	 37	(44.58)	 31	(37.35)	 15	(18.07)	Usually	 30	(10.45)	 		9	(30.00)	 		8	(26.67)	 13	(43.33)	Always	 27	(09.41)	 15	(55.56)	 		5	(18.52)	 		7	(25.93)	
	
Sun-protective	measures:	seek	shade	(n=291)*																																																																				Rarely	or	never	 82			(28.18)	 26	(31.71)	 34	(41.46)	 22	(26.83)	 0.000	Sometimes	 114	(39.18)	 52	(45.61)	 42	(36.84)	 20	(17.54)	Usually	 68			(23.37)	 35	(51.47)	 14	(20.59)	 19	(27.94)	Always	 27			(9.28)	 14	(51.85)	 		4	(14.81)	 		9	(33.33)	
		
49 
First	notice	of	the	dark	spot	made	(n=295)*		By	patient	 					286	(96.9)	 126	(44.06)	 89	(31.12)	 71	(24.83)	 0.754	By	doctor	 	6			(02.00)	 2					(33.33)	 2			(33.33)	 2			(33.33)	 	By	others	 					3			(01.00)	 1					(33.33)	 2			(66.67)	 0	 		
Patient	first	used	resources	for	help	(n=293)*	Internet	 				37	(12.60)	 			9	(24.32)	 21	(56.76)	 				7(18.92)	 0.002	Friend	 				32	(10.90)	 	17	(53.12)	 		7	(21.88)	 			8	(25.00)	 0.392	Doctor	 		195	(66.60)	 	94	(48.21)	 53	(27.18)	 	48	(24.62)	 0.036	Family	member	 				24	(08.20)	 				7(29.17)	 13	(54.17)	 			4	(16.67)	 0.067	Other	 				13	(04.40)	 			3	(23.08)	 5	(38.46)	 			5	(38.46)	 0.236	
	
Previous	knowledge	about	hyperpigmentation	disorders§	(n=296)*	Post-inflammatory	hyperpigmentation	 78	(27.18)	 17	(21.79)	 49	(62.82)	 12	(15.38)	 0.000	Melasma	 		76	(26.21)	 43	(56.58)	 19	(25.00)	 14	(18.42)	 0.027	Lentigo/sun	spots	 119	(41.90)	 50	(42.02)	 38	(31.93)	 31	(26.05)	 0.942	Freckles	 179	(61.72)	 78	(43.58)	 60	(33.52)	 41	(22.91)	 0.513	Moles/nevi	 154	(54.61)	 54	(35.06)	 59	(38.31)	 41	(26.62)	 0.018		
Use	of	OTC	lightening	creams	(n=292)*	Yes	 147	(50.30)	 79	(53.74)	 48	(32.65)	 20	(13.61)	 0.000	No	 138	(47.30)	 43	(31.16)	 46	(33.33)	 49	(35.51)	Don’t	know	 				7	(02.40)	 		5	(43.49)	 		0	(00.00)	 	2		(28.57)		
Monthly	spending	on	OTC	(n=277)*	$0	 107	(38.63)	 32	(29.91)	 38	(35.51)	 37	(34.58)	 0.001	<$50	 132	(47.65)	 63	(47.73)	 40	(30.30)	 29	(21.97)	>=$50	 27			(09.75)	 19	(70.37)	 	7		(25.93)	 	1		(03.70)	>	$100	 11			(03.97)	 	7		(63.64)	 	3		(27.27)	 	1		(09.09)	
	
Where	products	where	obtained	(n=285)*	US	pharmacy	 	149	(50.00)	 69	(46.31)	 55	(36.91)	 25	(16.78)	 0.006	Abroad	 			25	(08.39)	 18	(72.00)	 		3	(12.00)	 		4	(16.00)	 0.012	Community	store	 			17	(05.70)	 		9	(52.94)	 		5	(29.41)	 		3	(17.65)	 0.812	Friend	 			16	(05.37)	 11	(68.75)	 		4	(25.00)	 		1	(06.25)	 0.092	Not	applicable/	other	 			96	(32.21)	 26	(27.08)	 32	(33.33)	 38	(39.58)	 0.000	
Products	obtained	with	prescription	(n=298)*	Yes	 147	(49.80)	 86	(58.50)	 40	(27.21)	 21	(14.29)	 0.000	No	 146	(49.50)	 43	(29.45)	 52	(35.62)	 51	(34.93)	
	 	 	 	 	
Products	tried§	 	Hydroquinone	 124	 68	(54.84)	 37	(29.84)	 19	(15.32)	 0.000	Kojic	acid	 14	 3			(21.43)	 8			(57.14)	 3			(21.43)	 0.120	Azelaic	acid	 11	 5			(45.45)	 6			(54.55)	 0			(00.00)	 0.033	Tri-luma	 40	 28	(70.00)	 5			(12.50)	 7			(17.50)	 0.000	Antioxidants	 3	 0			(00.00)	 2			(66.67)	 1			(33.33)	 0.400	Steroid	cream	 18	 3			(16.67)	 8			(44.44)	 7			(38.89)	 0.115	
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Use	of	birth	control	(n=298)*	Yes	 204	(68.46)	 97	(47.55)	 56	(27.45)	 51	(25.00)	 0.042	No		 94			(31.54)	 33	(35.11)	 39	(41.49)	 22	(23.40)	
	
Thyroid	medication	(n=257)*	Yes	 		20	(07.80)	 			6		(30.00)	 	5		(25.00)	 		9	(45.00)	 0.291	No		 228	(88.70)	 102	(44.74)	 72	(31.58)	 54	(23.68)	Don’t	know	 				9	(03.50)	 			3	(33.33)	 		4	(44.44)	 		2	(22.22)	
	
Family	member	with	same	condition	(n=)*	Yes	 104	(35.30)	 39	(37.50)	 35	(33.65)	 30	(28.85)	 0.603	No		 157	(53.20)	 73	(46.50)	 49	(31.21)	 35	(22.29)	Don’t	know	 	34	(11.50)	 16	(47.06)	 11	(32.35)	 7			(20.59)	
	
How	much	condition	bothered	participants	(n=298)*	Very	much	 162	(54.36)	 78	(48.15)	 54	(33.33)	 30	(54.36)	 0.233	A	lot	 		92	(30.87)	 35	(38.04)	 27	(29.35)	 30	(32.61)	A	little	 		35	(11.74)	 13	(37.14)	 12	(34.29)	 10(28.57)	Not	at	all	 				9	(03.02)	 		4	(44.44)	 		2	(22.22)	 	3	(33.33)	
	
Patient	belief	about	who	best	to	treat	their	condition	(n=292)*	Primary	care	doctor	 					2	(00.07)	 		2	(100.00)	 		0	(00.00)	 		0	(00.00)	 0.356	Dermatologist	 283	(96.90)	 123	(43.46)	 91	(32.16)	 69	(24.38)	Aesthetician	 					1	(00.03)	 						0	(0.00)	 				0	(0.00)	 1	(100.00)	Friend	who	has	same	condition	 				1	(00.03)	 						0	(0.00)	 1	(100.00)	 				0	(0.00)	Other	 				5	(01.07)	 			1	(20.00)	 2	(40.00)	 	2	(40.00)	§	Attributes	are	not	mutually	exclusive;	therefore,	total	percentages	were	not	generated.	
*			Denominators	might	differ	due	to	missing	data.	
 	Generated	through	either	chi-square	test,	fisher	exact	test,	or	t-test	when	appropriate.	¤	Fisher-exact	test	value	was	not	possible	to	generate	due	to	small	sample	size.	
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A total of 102 (48.6%) patients reported use of sunscreen with sun protection 
factor (SPF) 21 to 50. We found that those with melasma used the recommended SPF of 
21–50 more often than those diagnosed with PIH and others (p<0.008).  Moreover, those 
diagnosed with melasma applied sunscreen 2 to 3 times a day more often than those with 
PIH and others. The comparison between groups was significant at p<0.001. 
During peak hours, between 10am to 4pm, most patients 182 (65%) and 165 
(57.5%) reported staying outside for 1 hour or less on weekdays and weekends, 
respectively. When outdoors, more than half of patients rarely or never wore a hat 147 
(51.2%) and only 27 (9.3%) reported always and 68 (23.4%) usually seeking shade. More 
patients with PIH reported rarely or never seeking shade when compared with patients 
with other hyperpigmentation disorders. More patients with melasma reported usually 
and always seeking shade (p <0.001). 
 
4.1.6 Patients’ beliefs, attitudes and practices towards skin hyperpigmentation  
The skin hyperpigmentation was self-perceived by the vast majority (286, 97%) 
of patients. The predominant source of information used by patients to gain knowledge 
about their skin condition was the medical doctor. Interestingly, the internet was shown 
to be the first resource used by those diagnosed with PIH when compared with other 
groups (p<0.002), whereas those diagnosed with melasma were more likely to seek 
medical help (p<0.036) (Table 7). The vast majority (238, 96.9%) of patients reported 
that the best person to treat their dark spot(s) is the dermatologist.  No significant 
difference was found between melasma, PIH, and other groups. 
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To assess general knowledge about common hyperpigmentation conditions, patients 
were asked if they had ever heard of post-inflammatory hyperpigmentation, melasma, 
lentigo or sun spots, freckles, and moles or nevi. Sixty-seven percent of patients have 
previously heard of freckles, 54.61% moles/nevi, and 41.90 % of lentigo/sunspots. Those 
diagnosed with PIH (62.82%) were significantly more likely to have prior knowledge of 
their condition than those with melasma (21.79%) and other hyperpigmentation disorders 
(15.38%) at p<0.001. Similarly, those diagnosed with melasma (56.58%) were more 
likely to have heard of the condition “melasma” when compared with PIH (25%) and 
other hyperpigmentation disorders (18.3%) at p< 0.027. The use of over-the-counter 
lightening creams was reported by 147 (50.30%) of patients. Those with melasma (53%) 
were more likely to try an over-the-counter lightning cream when compared with PIH 
(32%) and others (18%). Those with other hyperpigmentation disorders were less likely 
to try over-the-counter creams when compared with the other two groups, which was 
significant at p<0.001.  
 
The average monthly expenditure on skin lightning products reported by most 
patients (47.65%) was less than 50 dollars. Those with melasma were more likely to 
spend ≥ $50 (70.31%) on skin products compared with those with PIH (25.93%) and 
other hyperpigmentation (3.70%), respectively (p<0.001). Nearly half of products tried 
by patients were obtained with a prescription (147, 49.80%) from a pharmacy in the 
United States (149, 50%). Only 10% of patients obtained the products from 
overseas/abroad. Those diagnosed with melasma (72%) obtained products from abroad 
		
53 
more frequently compared with those diagnosed with PIH (12%) and other 
hyperpigmentation disorders (16%) (p <0.012).  Patients with melasma (58.50%) were 
more likely to be prescribed a lightening product compared with PIH (27.21) and others 
(14.29) (P<0.001). 
 
Hydroquinone had reported use by 43.15% of patients, 31.5% of which reported 
improvement of hyperpigmentation. The average time of hydroquinone use was less than 
3 months in 48.4%, followed by 3 to 5 months in 21.4% of patients. About 30% of 
patients used hydroquinone for periods longer than 6 months. Patients with melasma 
were more likely to be prescribed hydroquinone (54.85%) compared to those with PIH 
(29.84%) and other hyperpigmentation disorders (15.32%). Those with melasma were 
more likely to have tried triple combination cream (specifically Tri-luma® ) (28, 70%) 
than those with PIH (5, 12.5%) and others (7, 17.5%) (P<0.001). Almost two thirds of 
patients reported that they do not have a favorite brand of skin care products for their 
hyperpigmentation disorder. The use of birth control was reported by 52.75% of patients. 
Those diagnosed with melasma (47.55%) were found to be significantly more likely to 
use birth control compared with PIH (27.45%) and other hyperpigmentation disorders 
(25%) at p< 0.042 (Table 7). When questioned if they have ever tried skin lightening 
cream containing kojic acid, azelaic acid, antioxidants, and steroids,  only a small 
percentage responded yes (5%, 4%, 9%, and 6.6% respectively), and the vast majority 
answered no or don’t know.  
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4.2 Correlation  
4.2.1 Correlation between quality of life measures and clinical disease severity 
measures. 
To crudely validate SDIEQ against DLQI and to understand how measures of 
quality of life relate to the actual clinical severity of the disease, a correlation matrix was 
constructed among DLQI, SDIEQ, PAHI, and MASI. SDIEQ demonstrated a strong 
correlation with DLQI (spearmans’ rho coefficient 0.79, p <0.001), while PAHI 
correlated weakly with both DLQI (spearmans’ rho coefficient 0.07, p = 0.65) and 
SDIEQ (spearmans’ rho coefficient 0.074, p = 0.6 value). MASI had a weak but 
significant correlation with DLQI (spearmans’ rho coefficient 0.32, p <0.001) and SDIEQ 
(spearmans’ rho coefficient 0.31, p <0.002 value). See Figure 1. 																					
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Figure 1. Correlation between quality of life scores and clinical disease severity 
scores. 		
	 DLQI§					n			=	49	SR=0.07	p		=0.65	 		
PAHPI§	
	n			=146	SR=0.32	p		=	0.0001	 		
	 MASI≈	
			n			=196	SR=0.79	p			=0.00	 	 	 	
SDIEQ§	
	 	 n			=50	 n			=97	SR=0.074	p			=0.60	 SR=0.31	p		=	0.002	SR=	Spearman’s	rho	coefficient	
≈ Score was converted to log to approximate normality. 
§ Score was converted to square roots to approximate normality. 
 
4.3 Bivariate Analysis 
4.3.1 Association between DLQI score and clinical diagnosis   
 In order to examine the association between DLQI and clinical diagnosis, a bivariate 
analysis was performed, and a positive association was found between the overall DLQI 
(square roots) and melasma versus others (p=0.003) and PIH versus others (p<0.001). 
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The results suggest that patients with PIH have significantly worst quality of life than 
those with other hyperpigmentation disorders and those with melasma have significantly 
worse quality of life than those with other hyperpigmentation disorders. (Table 8).  
Table 8. Bivariate Analysis for the association between DLQI score and clinical 
diagnosis    
Attribute n (%)  Mean /n(%) 
Melasma 121 6.75* 
PIH 91 7.89** 
Others 70 4.5 
* p<0.05 for the comparison melasma vs. others 
**p< 0.05 for the comparison PIH vs. others 
 
4.3.1 Association between DLQI score and clinical diagnosis   
 In order to examine the association between DLQI and clinical diagnosis, a 
bivariate analysis was performed, and a positive association was found between the 
overall DLQI (square roots) of melasma versus others (p=0.003) and PIH versus others 
(p<0.001). Interestingly, in our study population, patients with PIH have significantly 
worse DLQI than patients with melasma (p <0.005) (Table 8).  
 
4.4 Multivariate Models 
4.4.1 Factors Associated with Patient Knowledge of Their Diagnosis (Table 6) 
In a logistic regression analysis performed to study factors associated with higher 
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likelihood of patients’ knowledge of their diagnosis, a higher level of education, younger 
age, longer duration of having the condition, and current use of sunscreen were found to 
have 2.4, 2, 3.7, and 2.4 significantly higher odds of diagnosis knowledge. Results can be 
seen in Table 9. Those with college degrees were 2.4 times more likely to know their 
diagnosis compared with those with middle school education or less (p =0.05). Those 
younger than 45 years were 2.1 times more likely to know their diagnosis compared with 
those with 45 years or older (P=0.04).  A higher likelihood of knowing the diagnosis was 
observed among those with disease duration up to 5 years compared with those with 1 
year or less (P=0.03). Those that used sunscreen were 2.4 times more likely to know the 
diagnosis compared with those that did not use sunscreen (P=0.02). Surprisingly, visit 
type (first visit vs. follow-up) was not shown to be statistically different in evaluating for 
diagnosis recognition (Table 9). 
 
	 	
		
58 
Table 9. Factors associated with higher odds of patients’ knowledge of their 
diagnosis. 
	
Dependent	Variables	 N					(%)	 Odds	
ratio§	 p	value	 Confidence	Interval	
Level	of	education	Middle	school	diploma	or	less	(reference)	 68			(23.37)	 	High	school	diploma	 95			(32.65)	 0.87	 0.78	 (0.31,	2.38)	College	or	graduate	degree		 128	(43.99)	 2.48	 0.05	 (0.97,	6.31)	
Age	>45	years	old	(reference)	 103	(34.56)	 	
≤45	year		 195	(65.44)	 2.15	 0.04	 (1.05,	4.43)	
Visit	type	First	visit	(reference)	 122	(46.04)	 	Second	visit		 143	(53.96)	 0.87	 0.69	 (0.45,	1.68)	
Duration		Up	to	1	year	(reference)	 40			(16.60)	 	Up	to	5	years	 101	(41.91)	 3.72	 0.03	 (1.14,	12.07)	
≥	15	years		 100	(41.49)	 3.12	 0.06	 (0.95,	10.28)	
Use	of	Sunscreen	No	(reference)	 85			(29.72)	 	Yes	 201	(70.28)	 2.44	 0.02	 (1.12,	5.33)	
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4.4.2 Factors Associated with DLQI scores  
The type of hyperpigmentation disorder and disease duration were both factors 
associated with a change in DLQI scores. Those with melasma have an increase of 0.62 
in DLQI score in comparison with those with other hyperpigmentation disorders 
(p<0.002). Similarly, those diagnosed with PIH have an increase of 0.98 in DLQI score 
compared with reference group (p<0.001) (Table 10). 	
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Table 10. Factors associated with DLQI scores. 																		
			§	DLQI total scores were transformed to square roots of total scores to approach normal 
distribution.
Dependent	Variables	 Change	in	
DLQI	score§	 p	value	 Confidence	Interval	
 
Hyperpigmentation disorder 
   
Other hyperpigmentation disorder (reference)   
Melasma 0.62 0.002 (0.220,1.01) 
PIH 
 
0.98 0.000 (0.53,1.43) 
Duration  
Up to 1 year (reference)  
Up to 5 years -0.44 0.049 (-0.88, -0.01) 
≥ 15 years 
 
-0.55 0.017 (0.95, 10.28) 
Level of education 
Middle school diploma or less (reference) 
High school diploma -0.019 0.93 (-0.44, 0.40) 
College or graduate degree 
 
-0.14 0.54 (-0.56, 0.29) 
Visit type 
First visit (reference)  
Second visit 
 
0.87 0.69 (0.45, 1.68) 
Age 
>45 years old (reference)  
≤45 year 
 
0.18 0.327 (-0.18, 0.55) 
Use of Sunscreen 
No (reference)  
Yes 
 
0.21 0.24 (-0.14, 0.57) 
Knowledge of the diagnosis    
No (reference)    
Yes 0.12 0.51 (-0.25, 0.5) 
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CHAPTER FIVE: DISCUSSION 		
Although disorders of hyperpigmentation are often benign conditions that do not 
impair physical health, they are commonplace in clinical practice and can carry adverse 
psychological outcomes for patients (S. J. Kang et al. 2014). Despite the fact that there 
are numerous studies evaluating quality of life in melasma patients (Pawaskar et al. 2007) 
(Ikino et al. 2015) (Pichardo et al. 2009), little is known about the effect of other common 
and uncommon hyperpigmentation disorders on quality of life (A. Taylor et al. 2008). 
Health related quality of life is defined as individuals’ self- perception of their position in 
life (WHOQOL, 1993), which can vary according to culture and value system. It is a 
concept that captures the effect of a certain disease on a person’s life as perceived by that 
person (Chen 2012). 
 
For example, males and females may react differently to having a skin 
hyperpigmentation disorder. Although these disorders affect both genders, the frequency 
of women (70%) who seek ambulatory care for dyschromia is much higher than men 
(30%) [(S. J. Kang et al. 2014)], and the impact of these disorders on female patients’ 
quality of life is higher, regardless of the specific diagnosis (Tejada et al. 2011) (D 
Hexsel, Arellano, and Rendon 2006) (Linthorst Homan et al. 2009). This could be why 
females constituted the majority (90%) of our sample. Additionally, we observed a higher 
frequency of melasma cases, a common hyperpigmentation disorder in females [(Grimes 
2009)], which might have also contributed to the higher number of females in our sample. 
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The majority of our study population identified themselves as being Hispanic and/or 
Latinos. The higher number of Hispanics in this sample can be explained by the location 
of recruitment sites, which included a tertiary care center that cares for the underserved 
and a community health center located in East Boston, where the self-reported Hispanic 
or Latino rate is 52.8%, compared to the national average of 17.4% Hispanics living in 
US.  
 
Among hyperpigmentation disorders, melasma and PIH were the most common. 
The majority of those diagnosed with melasma were of Fitzpatrick skin phototype IV. 
This finding is consistent with the literature, melasma being more common in Fitzpatrick 
skin types III to IV (V. M. Sheth and Pandya 2011a). To complement clinical evaluation, 
wood’s light examination was performed to help identify the possible location of pigment 
deposition. As this examination is quite subjective, it remains unclear if this distinction 
has a true correlation with histological pigment depth and other clinical significance to 
treatment. In a study by Grimes et al. using wood’s light to evaluate pigment depth in 
patients skin types IV to VI, histological evidence of dermal melanin was found in 
wood’s light enhanced lesions that are consistent with epidermal melasma, moreover 
histological evidence of melanin was observed in the epidermis and dermis of all subjects 
(Grimes, Yamada, and Bhawan 2005).  
 
The second most common diagnosis in this sample was post-inflammatory 
hyperpigmentation, which, in agreement with previous literature, was more common 
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among those with skin types V–VI (Savory et al. 2014), with disease duration of longer 
than 10 years.  The effect of these two most common hyperpigmentation disorders on 
quality of life was compared to all other hyperpigmentation disorders. The magnitude of 
effect of all hyperpigmentation disorders on quality of life as measured by mean DLQI 
was 6.5 ± 5.3. Broken down, the DLQI mean for PIH and melasma was 7.89 and 6.75, 
respectively. It may be the case that the conditions classified as others in our setting 
might generally be perceived as more common types of hyperpigmentation disorders and 
therefore are associated with higher quality of life measurements. Overall, it has been 
noted that quality of life by definition is highly subjective and might not relate to disease 
severity (Jayaprakasam et al. 2002) (Balkrishnan et al. 2003). Therefore, the significantly 
lower quality of life for patients with melasma and PIH can still bring contextual 
understanding to the effect of these disorders on patients’ quality of life.  
 
The mean DLQI for melasma reported in previous studies ranged from 4.5 
(Harumi and Goh 2016), 7.3 (Leeyaphan et al. 2011) to 7.5 (Pichardo et al. 2009), and 
this is comparable to mean DLQI for melasma (6.75) obtained in our study. Only one 
study evaluating DLQI and PIH was found in the literature, and mean DLQI was 8.4 
(Joshi et al. 2009), this is slightly higher than our mean of 7.89.  In comparison to other 
dermatological conditions in the literature, the mean DLQI for the total sample was 
higher than non-melanoma skin cancer (NMSC) 2.4 (Rhee et al. 2004), vitiligo 4.9 
(Krüger and Schallreuter 2015), erythema of rosacea 6.2 (Bewley et al. 2016), acne scars 
5 (Chuah and Goh 2015), and lower than atopic dermatitis 8.5 (Beikert et al. 2014),  
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pemphigus vulgaris and foliaceus 10.2 (Sung, Roh, and Kim 2015), and psoriasis 12.74 
(Kouris et al. 2016).  
 
Although physicians use clinical disease severity as an important tool in decision 
making and evaluation of treatment efficacy, it has been shown that interpretation of 
HRQoL based on disease severity may be clinically unreliable (Jayaprakasam et al. 
2002). This is because — as discussed before — perception of HRQoL is highly 
subjective and is confounded by many other factors (Chen 2012).  To explore this aspect 
in our sample, the relationship between clinical severity and patient-reported quality of 
life for those who received a diagnosis with melasma and PIH was evaluated.  
 
The modified MASI score was used to evaluate melasma severity and mean score 
was 5.3± 3.46. This was much lower compared with those reported by Dominguez et.al 
(mean score 10) [(Dominguez et al. 2006)], and Freitag et al. (mean 10.6 ±6) [(Freitag et 
al. 2008)], suggesting that our patient population had milder disease severity. A possible 
explanation may be that patients had better access to health care and sought treatment 
early or they may have had prior treatment.  
 
 Moreover, MASI had a weak, although significant, correlation with DLQI scores 
(spearmans’ rho coefficient 0.32, p <0.001) and SDIEQ (spearmans’ rho coefficient 0.31, 
p <0.002 value) corroborating with other studies that clinical severity may not be the only 
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criteria used by patients to assess disease burden (Balkrishnan et al. 2003) (Dominguez et 
al. 2006).   
  
For PIH, the novel PAHPI total score was used (mean 10.32 ± SD 3.3) and most 
patients were classified as having very mild to mild disease severity. Although scores 
were very mild to mild, the mean DLQI (7.89) was significantly higher when compared 
with patients with other hyperpigmentation disorders, suggesting that although they may 
have had mild disease, it still significantly impacts their quality of life.  PAHPI, which 
also correlated weakly with the quality of life measurements, DLQI and SDIEQ 
(spearmans’ rho coefficient 0.07, p = 0.65) (spearmans’ rho coefficient 0.074, p = 0.6 
value). 
 
In the absence of a specific health-related quality of life instrument (HRQoL) for 
skin hyperpigmentation, we used the Skin Discoloration Impact Evaluation 
Questionnaire (SDIEQ) created by Balkrishnan et al., and the validated but not disease 
specific questionnaire developed by Finlay et al., Dermatology Quality of Life Index 
(DLQI) (Finlay and Khan 1994).  Although the DLQI is a reliable and easy to use 
HRQoL questionnaire, many questions focus on physical limitations and places less value 
on psychological impact of skin diseases (Nijsten 2012), making it better to assess 
inflammatory diseases but not ideal for conditions with a greater psychological impact 
such as hyperpigmentation disorders.  On the other hand, the Skin Discoloration Impact 
Evaluation Questionnaire (SDIEQ) is a brief questionnaire whose questions focus mostly 
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on patients’ feelings, experiences, effort placed on hiding discoloration, and effect on 
leisure and social activities. The SDIEQ could be a practical and short replacement for 
the DLQI; however, it is not validated for use in hyperpigmentation disorders. We aimed 
to assess how the two questionnaires correlated with each other in an attempt to roughly 
validate the SDIEQ. We found a strong correlation between the DLQI and SDIEQ 
(spearman rho of 0.79 p=0.00), which suggests that SDIEQ scores can acceptably reflect 
DLQI scores; however, further validation studies with more vigorous methodology are 
required to find out possible cut-off values for the SDIEQ that can accurately reflect 
patients’ quality of life. 
 
The two factors in our study that were significantly associated with DLQI are type 
of hyperpigmentation disorder and disease duration. One study with a much smaller 
sample size of 112 patients using different statistical analyses but similar categorization 
of disease duration demonstrated that patients with melasma for longer periods had 
significantly higher Spanish-language Melasma Quality of Life (Sp-MELASQoL). Of 
note, these patients also had higher MASI (Dominguez et al. 2006).  In contrast, we 
found that longer disease duration was associated with lower DLQI and better health-
related quality of life (HRQoL). The reason for this discrepancy and that our patient 
population feels that their skin condition is less of a burden over time needs to be further 
investigated. No correlation was found between DLQI and years of education, age, visit 
type, and use of sunscreen.  
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A large amount of patient (69%) reported that they did not know their diagnosis, 
the remaining of those patients reported they knew their diagnosis; however, only 30% 
actually had the correct diagnosis. Therefore, out of our total sample population, only 
30% knew their diagnosis correctly.  Multiple factors including poor health literacy, 
language barriers, and discordant diagnosis could be involved. On the other hand, most 
patients who knew their diagnosis had accurate perception (knowledge) regarding 
predisposing factors and generally adopted sun protective behaviors with 69% reporting 
using sunscreen. Of note, overall, few adopted other important sun protective measures 
such as seeking shade and wearing hats. The reported rate for sunscreen use in this study 
was similar to that reported for patients with multiple primary melanoma (70%) [(Warren 
et al. 2015)]. However, our study sample rate of sunscreen use was found to be not only 
be much higher than rates reported among the general population, 15% in men and 30% 
in women (Holman et al. 2015) but also higher than rates among those with 
photosensitivity disorders, at about 50% among patients with cutaneous lupus 
erythematosus (Vilá et al. 1999), and among patients with cutaneous malignancies such 
as single primary melanoma with 45–57% reporting sunscreen use. This raises the 
questions about motivational factors behind the use of sunscreen. A possible explanation 
might be related to the Hawthworn bias (Parsons 1974), in which respondents tend to 
modify or improve aspects of their behaviors when they are aware of being observed. 
Another explanation of this finding may be the gender imbalance in this study sample 
with 90% being female and that females are more likely to use sunscreen and other forms 
of sun protection than males (Altsitsiadis et al. 2012). Moreover, patients in this study 
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were presenting to a tertiary dermatological care center and this may have selected a 
more health conscious population. Patients who attributed their hyperpigmentation 
disorder to the sun were more likely to use and reapply the recommended SPF. This 
finding suggests that educating patients regarding their condition could possibly lead to 
increased compliance with sun protective measures. 
 
Regarding patients’ beliefs, attitudes, and practices towards skin 
hyperpigmentation, the vast majority of patients (97%) trusted dermatologist expertise to 
treat their skin disorder.   Most patients reported that they were the first to notice their 
skin lesions (self-perceived), and those with melasma and other hyperpigmentation 
disorders reported the medical doctor as the first source of information. Those with post-
inflammatory hyperpigmentation notably used the internet as the first source of 
information.  About half of the patients in this study reported the use of over-the-counter 
skin (OTC) lightening products, and this behavior was more common among patients 
with melasma. The prevalence of skin lightening use varies worldwide, ranging from 
26% in West Africa (Del Giudice and Yves 2002) to 60% in Jordan (Hamed et al. 2010), 
and 80% in African descendants living in Paris (Petit et al. 2006).  In our study, 31% of 
patients that used prescription hydroquinone for treatment of their hyperpigmentation 
reported improvement. Hydroquinone use is popular among patients with 
hyperpigmentation disorders (Nordlund, Grimes, and Ortonne 2006), and its reported 
improvement versus placebo in a clinical trial was around 40% (Ennes, Paschoalick, and 
Alchorne 2000).  Of note, about 30% of patients in our study who reported using 
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prescription strength hydroquinone used it for longer than 5 months. Therefore, it is 
important to educate patients about the side effects of long term use of hydroquinone 
containing products including allergic contact dermatitis, hyperpigmentation, nail 
discoloration, and exogenous ochronosis among others (Ladizinski, Mistry, and Kundu 
2011). Given the widespread use of skin lightening products, it is important that 
dermatologists discuss in detail the amount and location to apply the cream and treatment 
duration. Patient should be aware that although effective, hydroquinone-containing 
products should be used for short amount of time and other agents are available for 
maintenance therapy. 
 
Although both melasma and PIH treatments are quite similar being based upon 
sun protection and topical agents as first line therapy, many more melasma patients than 
PIH patients were prescribed hydroquinone and triple combination cream. This could be 
interpreted in different ways, treating physicians may not be aware of the importance of 
early treatment of PIH in darker skin types, as the condition may fade with time or simply 
patients are not familiar or do not discuss treatment options with their physician. 
Coinciding with this, monthly expenditure with skin lightening products was higher in 
patients diagnosed with melasma.  Also, melasma patients were significantly more likely 
to obtain products from abroad. We hypothesize that this could be due to higher 
medication cost in U.S. pharmacies, additionally most of our sample was non-US born 
and likely have access to medications from their home countries. Of note, patients were 
not always aware of the ingredients in their lightening creams, and only few reported they 
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had tried kojic acid (5%), hydroquinone (43.1%), azelaic acid (4%), antioxidants (9.1%), 
and steroids (6.6%).  
 
Hormonal contraceptives are associated with triggering and worsening of 
melasma (J P Ortonne et al. 2009). We found that the use of birth control methods 
(47.5%) was significantly higher in our melasma patients, and the percentage was 
comparable to the reported rates of hormonal contraception (53%) by Ortonne et al.(J P 
Ortonne et al. 2009).  This is likely attributed to the majority of patients being of 
reproductive age, yet as hormonal contraception is a possible melasma trigger it is 
important to counsel patients case by case regarding non-hormonal birth control options. 
  
When patient’s knowledge about their disease is not adequate this is likely to 
result in poor treatment compliance (J. Lin et al. 2008). We found factors of a higher 
level of education, younger age, longer duration of having the condition, and current use 
of sunscreen to have 2.4, 2, 3.7, and 2.4 significantly higher odds of knowing their 
diagnosis. The significant association with sunscreen (p<0.02) suggests that appropriate 
knowledge and understanding of one’s skin disorder plays an important role in treatment 
compliance.  Additionally, age younger that 45 years old was associated with a higher 
odds of diagnosis knowledge. This could possibly be explained by younger patients being 
more concerned by their skin appearance and therefore seeking information and/or 
medical help sooner than older patients. Therefore, patients 45 years or older with less 
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years of formal education and those newly diagnosed may benefit from appropriate 
education and counseling time by their treating physician.  
 
 
Limitations 
Although our sample was racially and ethnically diverse, our results may not be 
fully generalizable given our recruitment sites that provide care for an underserved 
population and one that is located in a primarily Hispanic area. Our results from DLQI 
and SIEDQ may be overestimated as these patients were seeking dermatologic treatment 
in a center specialized in ethnic skin. Furthermore, this study is based mostly on self-
reported information, which is subject to recall bias. Another limitation was the use of 
DLQI to assess the impact of melasma on QoL, in spite high correlation with Melasma 
Quality of Life (MELASQoL) scale.  Because of this, emotional and psychosocial aspects 
may have been neglected. Also patients unwilling to complete our survey were excluded, 
which was 17 correlating to 5.7% of patients questioned. Due to sample gender disparity, 
we did not include gender in the multivariate analysis and this is factor related to quality 
of life. 	  
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CHAPTER SIX: CONCLUSION 	
The effect of hyperpigmentation disorders on patients’ quality of life is not 
negligible and was found to be higher for those complaining of melasma and PIH in this 
study. Furthermore, the magnitude of effect on their quality of life was not correlated 
with the clinical severity. This signifies the importance of using a holistic approach that 
seeks to explore, acknowledge, and find ways to mitigate the difficulties inflicted by 
hyperpigmentation disorders on patients’ life, regardless of the clinical severity. Extra 
care should be taken regarding eliciting discussion with patients complaining of melasma 
and PIH, and those who had the disease for less than one year, given the significantly 
higher impact on their perceived quality of life found in this study. We found that 
patients’ who are younger, who use sunscreen more, who had the disease longer, and who 
had higher years of education are more likely to know their diagnosis. Patient’s 
knowledge of the diagnosis is associated with better compliance (J. Lin et al. 2008); 
therefore, making sure that the patient is aware of his/her diagnosis should be a priority 
during every medical encounter. Although all patients should be educated about their 
diagnosis, more time should be spent educating those who had high school education or 
less, those who use sunscreen less, and who are older than 45 years of age about their 
disease.  Given the percentage of those who were not aware of their diagnosis (69%), a 
review of the methods of communication between dermatologists and patients are 
needed. One of the reasons for patients’ failure to know their diagnosis might be 
attributed to language barriers (Partida 2007), use of education-level inappropriate 
language, or  a language that is heavily infiltrated with scientific/medical jargon . Further 
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studies are needed to examine specific factors associated with patients’ failure to know 
their dermatological diagnosis to mitigate this problem and create a more patient-centered 
approach. An overwhelming 97% of patients view the dermatologist as the best person to 
treat their condition, so it is our responsibility to accurately diagnose, treat, and counsel 
patients while not underestimating the impact of skin hyperpigmentation on patients’ 
daily life. 
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APPENDIX 
APPENDIX I. Informed consent RESEARCH	CONSENT	FORM	
Title of Project: Skin Hyperpigmentation Questionnaire                                                          
Principal Investigator: Neelam Vashi 
__________________________________________________________________ 
Background  
You are being asked to participate in a research study because you have: skin hyperpigmentation 
(dark/brown spots) on your face or body. 
The study will involve a onetime questionnaire survey with questions aimed at learning more 
about your knowledge and the effects of your skin condition has had on your life. Your 
participation in this study will only be for the day that you fill out the survey. Please read 
the information carefully. If you have questions please ask the investigator or study staff. 
You should only complete this survey when you feel completely informed. If you read 
any words that are not clear to you, please ask the Principal investigator or study personal 
to explain them to you. 
 
 Purpose  
This is a research study to find out more about your attitudes and the impact of your skin 
condition in your life. You will be one of approximately 200–300 subjects to be asked to 
participate in this study.  
The research will take place at the following location(s): BMC and EBNHC  
After you agree to be in this study, a study investigator will provide you with the survey 
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form to be completed in one sitting. The survey will consist of 32 questions related to 
your current perception of your health and skin condition. You may skip any questions 
that make you feel uncomfortable. Survey completion will take approximately 15 minutes 
total. This survey will be anonymous and there will be no questions that will ask for any 
identifying information. 
 
Right to Refuse or Withdraw  
Taking part in this study is voluntary. You have the right to refuse to take part in this 
study. If you decide to be in the study and then change your mind, you can withdraw 
from the research. Your participation is completely up to you.  
 
Subject's Rights  
By consenting to participate in this study you do not waive any of your legal rights. 
Giving consent means that you have heard or read the information about this study and 
that you agree to participate. You will be given a copy of this form to keep.  
You may obtain further information about your rights as a research subject by calling the 
Office of the Institutional Review Board of Boston University Medical Center at 617-
638-7207. The investigator or a member of the research team will try to answer all of 
your questions. If you have questions or concerns at any time, contact the PI, Dr. Neelam 
Vashi and Co-investigator: Mayra Maymone at (857) 206-3895.  
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APPENDIX II. Inclusion and exclusion criteria 
Inclusion criteria 
1. Individuals 18 years or older 
2. Individuals referred to dermatology for any hyperpigmentation disorder 
3. Individuals willing and able to answer the questionnaire in English, Portuguese, 
or Spanish. 
Exclusion criteria 
 
1. Individuals who do not speak English, Portuguese, or Spanish 
2. Any patient who cannot give consent due to intellectual disability 
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APPENDIX III. Non-validated skin questionnaire 
Skin Hyperpigmentation Questionnaire 
 
Have you taken this survey before?     1  Yes   2 No à END SURVEY IF “YES”  
 
Age:    _______ years                                    
Gender:   1 Female     2 Male                                                        
Were you born in the USA:  1  Yes   2 No à Country of Origin (specify):  ________                                          
Primary language spoken:   1  English 2 Spanish   3 Portuguese 4  French 
5 Other (specify): _____________ 
Race (check all that apply):  1 White  2 Black or African American 
 3 Asian    4 American Indian or Alaska Native 5 Native 
Hawaiian or other Pacific Islander 
Ethnicity:    1 Hispanic or Latino 2 Not Hispanic or Latino 
Job/occupation:  1 Not working 2 Working à Occupation: 
________________           
Marital Status:   1 Single 2 Married 3 Separated 4 Widowed 
5  Living in common law     6 Divorced 
Education (highest): 1 Lower/elementary school 2 Middle school 3 High school 
diploma 
4 College degree 5 Graduate school 
 
 
We would like to know more about you and your skin care. 
Please check the box that best describes your answer. 
 
1. Where do you have dark/brown spots? (check all that apply) 1  Face 2 Body   
      How long have you had dark/brown spots? 
1 1–6 months 2 7–12 months 3 1–5 years 4 5–10 years 5 10–15 years 6 >15 years 
 
2. Do you think the dark/brown spots are due to the sun? 1 Yes 2 No 3 I don’t know 
If not from the sun, what do you think they are from?__________________________ 
 
3. Do you think the dark/brown spots are caused by  
a. Your genetic background?     1 Yes 2 No 3 I don’t know  
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b. Pregnancy or hormones?  1 Yes 2 No 3 I don’t know  
c. Previous acne spots or rash?  1 Yes 2 No 3 I don’t know 
 
4. Are you currently using a lotion, cream, or sunscreen with Sun Protection Factor 
(SPF)?                                             1 Yes 2 No  3 I don’t know 
 
               If  YES, what Sun Protection Factor (SPF) are you using?                                                 
 1 10–20 2 21–50 3 51–100  4  >100 5 I don’t know 
    If  YES, how often do you re-apply sunscreen?                              
 1 Every 2 hours   2 3 x day   3 2 x day  4 1 x day   5 Occasionally
 6 Almost never   
               If  YES, is your sunscreen broad spectrum?    
                  1 Yes 2 No  3 I don’t know  
 
5. 5On average, how many hours are you in the sun between 10 am – 4 pm?                                                         
  
   Weekends:  1 1 or less 2 2 3 3 4 4 5 5 6 6 
 
   Weekdays:  1 1 or less 2 2 3 3 4 4 5 5 6 6 
 
 
6. When you are outdoors in the sun, how often do you do each of the following? 
 
  Wear a hat:  1 Rarely or never  2 Sometimes   3 Usually   4 Always 
 
  Stay in shade or under umbrella: 1 Rarely or never 2 Sometimes   3 Usually   
4 Always 
                             
7. Do you think your ethnicity or racial background makes you more prone to have dark 
spots? 
1 Yes 2 No 3 I don’t know 
 
8. Do any of your family members have the same skin condition? 
1 Yes 2 No 3 I don’t know 
9. How much do the dark/brown spots bother you? 
1 Very much 2 A lot 3 A little 4 Not at all 
 
10. What is the name/diagnosis of your brown spots?  
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1 Post-Inflammatory Hyperpigmentation 
2 Melasma 
3 Solar Lentigo/sun spots 
4 Freckles 
5 Moles/nevi 
6 Other:________________________ 
7 I don’t know 
 
11. Have you ever heard of the following before?   
 
             Post-Inflammatory Hyperpigmentation? 1 Yes 2 No   
              
             Melasma? 1 Yes  2 No   
   
             Solar Lentigo/sun spots? 1 Yes 2 No  
 
        Freckles? 1 Yes 2 No  
 
        Moles/nevi? 1 Yes  2 No   	
12. Did you first notice the dark/brown spots or did your doctor? 
1 Me    2 The doctor    3 Other: __________________________. 
 
13. Where did you first go for help for your dark/brown spots?  
1 Internet    2 Friend 3 Doctor 4 Family member
 5 Other:_____________ 
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14. Have you ever tried any over-the-counter lightening creams? (include all the products 
you remember) 
1 Yes 2 No    3 I don’t know  
          
   If YES, what product have you tried? _________________________________ 
   Did it help lighten the dark/brown spots? 
             1 Yes 2 No 3 I don’t know 
    
   If YES, what product have you tried? _________________________________ 
   Did it help lighten the dark/brown spots? 
             1 Yes 2 No 3 I don’t know 
 
   If YES, what product have you tried? _________________________________ 
   Did it help lighten the dark/brown spots? 
             1 Yes 2 No 3 I don’t know 
 
   If YES, what product have you tried? _________________________________ 
   Did it help lighten the dark/brown spots? 
             1 Yes 2 No 3 I don’t know 
 
15. How much do you think you spend monthly on “over-the-counter” products to help 
your dark/brown spots?  1 $0  2  < $30   3 $30–50 4 $50–100 5 >$100 
 
16. Do you believe that the more expensive medicines/products help lighten your 
dark/brown spots more?      1 Yes 2 No 3 I don’t know  
 
17. Where did you get the cream that helped your dark/brown spots? (check all that 
apply) 
1 US pharmacy   2 Abroad/home country 3  Community/neighbourhood store   
4 Got from a friend 5  Not relevant  5 Other: _________________________ 
 
18. Have you ever used a prescription product to help lighten your dark/brown spots? 
1 Yes 2 No 3 I don’t know 
 
                 If YES, did you consult a doctor/physician to obtain the product? 
                              1 Yes 2 No 3 I don’t know  
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19. Have you ever used a product containing any of the following? 
a. Hydroquinone?  1 Yes  2 No         3 I don’t know  
If YES, did the dark/brown spots become lighter? 1 Yes  2 No 3 I don’t know    
   
If YES, what is the longest amount of time that you used it for?  
1 < 3 months    2 3–5 months    3 6–12 months    
4 1–5years     5 5–10 years    6 >10 years 
 
 b. Kojic Acid? 1 Yes       2 No 3 I don’t know  
If YES, did the dark/brown spots become lighter? 1 Yes 2 No 3 I don’t 
know  
    
  c. Azelaic Acid?  1 Yes  2 No   3 I don’t know 
If YES, did the dark/brown spots become lighter?  1 Yes 2 No 3 I don’t know  
 
  d. Tri-luma?   1 Yes  2 No             3 I don’t know 
 If YES, did the dark/brown spots become lighter? 1 Yes 2 No 3 I don’t know  
              
        e. Antioxidants?   1 Yes               2 No 3 I don’t know 
 If YES, did the dark/brown spots become lighter? 1 Yes 2 No  3 I don’t know  
 
        f. Steroid cream?              1 Yes    2 No  3 I don’t know  
If YES, did the dark/brown spots become lighter? 1 Yes 2 No 3 I don’t know  
 
20. Do you have a personal brand of products that you feel is better to treat dark/brown 
spots? 
      1 Yes 2 No      3 I don’t know 
 
  If YES, please write the name and/or brand: ____________________________ 
 
21. Have you ever used any of the following? 
a. Birth control?  1 Yes        2 No 3 I don’t know 
If yes, what type do you use? 
1 Copper IUD 2 Oral contraceptive 3 Mirena/skyla IUD  
4 Depo-shot 5  Implanon 6 Other: ___________________ 
b. Thyroid medication? 1 Yes  2 No   3 I don’t know 
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22. Do you think that the best person to help treat your skin condition is: 
1 Primary care doctor 2 Dermatologist 3 Aesthetician 
4 Friend who has the same skin condition 5 Other: 
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To be completed by MD 
Date:                                                                     Study Number:  
Diagnosis:                                                              
Skin type:  1 I        2  II 3 III 4 IV 5 V 6 VI  
First visit 1     or    Follow-up visit from:   2 BMC/EBNC 3 Outside Dermatology 
 
BSA:                                   Body site: 
MASI modified score:     
Melasma pattern:   Centro-facial      Malar      Mandibular    Combined     Body 
site:  
Wood’s light:   Epidermal     Dermal      Mixed     Inapparent 
Forehead:  
Left Malar + Right malar: 
Chin: 
 
Modified MASI score: Forehead 0.3 (D) Area + right malar 0.3 (D)Area + left malar 0.3 
(D)A + chin 0.1 (D)A.  
Area  
0=no involvement 
1=<10% 
2=10–29% 
3=30–49%  
4=50–69%  
5=70–89%  
6=90–100% 
 
 
 
Scoring the postacne hyperpigmentation index 
Darkness 
0=normal skin color 
1=barely visible  
2=mild hyperpigmentation; 
3=moderate  
4=severe 	
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Weighted score (S) Median lesion size 
2 <3 mm 
4 3–6 mm 
6 7–10 mm 
8 >10 mm 
Weighted score (I) Median lesion intensity 
3 Slightly darker than surrounding skin 
6 Moderately darker than surrounding skin 
9 Significantly darker than surrounding skin 
Weighted score (N) No. of lesions 
1 1–15 
2 16–30 
3 31–45 
4 46–60 
5 >60 
Total postacne hyperpigmentation index = S + I + N; score range: 6–22. 
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APPENDIX IV. DLQI  
DERMATOLOGY LIFE QUALITY INDEX                                      DLQI SCORE 
 
The aim of this questionnaire is to measure how much your skin problem has 
affected your life OVER THE LAST WEEK.  Please tick ➾  one box for each 
question. 
 
1. Over the last week, how itchy, sore, painful or stinging has your skin been? 
3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
 
2. Over the last week, how embarrassed or self-conscious have you been because 
 of your skin? 
3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant  
 
3. Over the last week, how much has your skin interfered with you going 
 shopping or looking after your home or garden?      
3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant  
 
4. Over the last week, how much has your skin influenced the clothes you wear? 
 3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant  
 
5. Over the last week, how much has your skin affected any social or leisure activities? 
 3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant  
 
6. Over the last week, how much has your skin made it difficult for you to do any sport? 
3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
 
7. Over the last week, has your skin prevented you from working or studying? 
3 Yes 0 No 0 Not relevant  
  
  If "No", over the last week how much has your skin been a problem at 
    work or studying?  2 A lot 1 A little  0 Not at all 
 
8. Over the last week, how much has your skin created problems with your partner or 
any of your close friends or relatives? 
 3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant  
 
9. Over the last week, how much has your skin caused any sexual difficulties? 
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 3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant  
 
10. Over the last week, how much of a problem has the treatment for your skin been, for 
example by making your home messy, or by taking up time?   
 3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
 
 
© A Y Finlay, G K Khan April 1992 www.dermatology.org.uk 	  
		
87 
APPENDIX V. Skin Discoloration Impact Evaluation Questionnaire (SDIEQ) 
Skin Discoloration Impact Evaluation Questionnaire 
 
Q1. Over the last week, how embarrassed or self-conscious have you been because of 
your skin? 
        3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
 
Q2. Over the last week, how much have people focused on your skin discoloration 
rather than on what you are saying or doing? 
          3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
 
Q3. Over the last week, how much the discoloration made you feel unattractive from 
others? 
          3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
 
Q4. Over the last week, how much efforts have you put into hiding your skin 
discoloration from other? 
       3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
 
Q5. Over the last week, how much has your skin affected any of your social or leisure 
activities? 
            3 Very much 2 A lot 1 A little  0 Not at all 0 Not relevant 
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• Structure and function of skin 
• Basic Dermatology 
• Sex transmitted disease and AIDS 
• Clinical Pathological Correlation 
• Clinical Dermatology 
• Cutaneous Microbiology 
• Photobiology 
• Dermatology surgery 
• Good clinical Practice in Clinical  
• Biostatistics 
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2. Doctorate in Dermatology 
• Dissertation: IRB submission and survey questionnaire with 330 subjects 
recruited 
• Clinical Dermatology 
 
 
Presentation and publications 
 
1.  Maymone M, Vashi NA.  Progressive Macular Hypomelanosis. In P. B. Love, R. 
V. Kundu (Eds.), Clinical Cases in Skin of Color: Adnexal, Inflammation, Infections, 
and Pigmentary Disorders (first edition).  London: Springer, ISBN 978-3-319-22391-
9, November, 2015. 
 
2. Vashi NA, Maymone M.  Approach and Resources.  In N. A. Vashi (Ed.), Beauty 
and Body Dysmorphic Disorder: A Clinician’s Guide (first edition).  New York: 
Springer Science + Business Media LLC, ISBN 978-3319178660, September, 2015. 
 
3.Vashi NA, Maymone M, Kundu RV.  Aging differences in ethnic skin. J Clin 
Aesthet Dermatol. 2016;9(1):31–38.    
 
4. Maymone M, Gan S, and Bigby M. (2014). “Evaluating the Strength of Clinical 
Recommendations in the Medical Literature: GRADE, SORT, and AGREE.” The 
Journal of Investigative Dermatology 134 (10): e25. doi:10.1038/jid.2014.335. 
 
5. Maymone M, Ho J, Vashi NA, Bhawan J, Generalized Dowling-Degos disease 
with a dyschromatosis universalis hereditaria-like phenotype. (2015). New England 
Dermatological Society, Boston University School of Medicine. 
 
6. Maymone M, Markova A, Vashi NA, Goldberg L. (2014). Facial papules in 
frontal fibrosing alopecia. New England Dermatological Society, Boston University 
School of Medicine. 
 
7. Larrocca C, Lam C, Maymone M. (2013). Diffuse Cutaneous Sarcoidosis, New 
England Dermatological Society, Boston University School of Medicine. 
 
8. Maymone M, Rattanasirivilai P, Gan S, Miller D. Rickettisialpox. (2012). New 
England Dermatological Society, Boston University School of Medicine. 
 
9. Maymone M et. al. (2010) Xeroderma Pigmentoso. Congresso Médico Cientifico 
Internacional Brasil/ Itália.   
 
10. Maymone M. (2010).  Ictiose Histrix. VI Jornada Academica de Medicina da 
Uniderp, Campo Grande. 2010. v.2. p.20 – 20. 
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11. Maymone M. (2010). Abscesso Orbitário Unilateral Decorrente Se Sinusite 
Aguda Em Neonato Com 24 Dias De Vida. VI Jornada Acadêmica de Medicina da 
Uniderp, Campo Grande. v.2. p.18 – 18. 
 
12.  Maymone M. (2010). Aneurisma De Jugular Externa. VIII Jornada Médica da 
Santa Casa-Dr. William Maksoud, 2010, Campo Grande. Aneurisma De Jugular 
Externa.v.2. p.23 – 23. 
 
 
 Oral presentations 
 
1. Maymone M, Vashi NA. Repigmentation of facial hypomelanosis with non-
ablative fractionated laser. (2016). Oral presentation at 36th Annual Conference 
of the American Society for Laser Medicine and Surgery, Boston, 2016. Boston, 
MA. 
 
2. Maymone M, Vashi NA. Skin Hyperpigmentation Disorders: Associations and 
Impact on Health-Related Quality of Life: Doctoral dissertation defense. Boston 
University Dermatology department. 
 
3. Maymone M, Sacht G (2010). Ictiose Histrix. VI Jornada Academica de Medicina 
da Uniderp, Campo Grande. 2010. v.2. p.20 – 20. 	
Poster Presentations 
 
1. Maymone M, Vashi NA, Kundu. (2016). Maturation Hyperpigmentation: A 
distinct entity. (2016). 12th Annual Skin of Color Scientific Symposium, 
Washington DC, 2016. 
 
2. Maymone, Mayra Buainain de Castro Maymone, Vashi, Neelam. Effective 
treatment of exogenous ochronosis with Q-switched alexandrite laser. 2016. 
Poster presentation at 36th Annual Conference of the American Society for Laser 
Medicine and Surgery, Boston, 2016. 
 
3. Maymone M, Vashi NA. Repigmentation of facial hypomelanosis with non-
ablative fractionated laser. (2016). Poster presentation at 36th Annual Conference 
of the American Society for Laser Medicine and Surgery, Boston, 2016. Boston, 
MA. 
 
Work in progress 
 
1. Skin Hyperpigmentation Disorders: Associations and Impact on Health-Related 
Quality of Life: Doctoral dissertation. 
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2. Comparing the Efficacy of Combined Glycolic Acid and Salicylic Acid versus 
Glycolic Acid Peel Alone in the Treatment of Melasma: A Split Face Study 
3. Barriers of Dermatological care at Boston Medical Center. 
 
Languages 
• Mother language: Brazilian Portuguese 
• Fluent in English 
• Spanish fluent spoken  
 
Computer Skills 
• Microsoft, Excel, and PowerPoint  
• Epic Medical Records 
• Ability to perform data entry and quality monitoring 
 
Other Skills 
• Highly motivated and hard-working 
• Excellent organizational skills 
 
Personal Life 
 
Married and mother of two girls. Enjoy reading, movies and ice skating.  
